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1CHAPTER I 
INTRODUCTION
Calcium (Ca2+) functions as an important intracellular element that 
underlies essential cellular processes including muscle contraction, synaptic 
transmission, secretion of hormones, and gene expression (Fill and Copello, 
2002; Zhang and Brown, 2004).  In the heart, Ca2+ is the signaling massager for 
cardiac excitation-contraction coupling (E-C coupling) which is a chain reaction, 
and Ca2+ concentration fluctuation can be converted to cardiac contraction and 
relaxation. Moreover, the intracellular calcium concentration [Ca2+]i should be 
finely adjusted to maintain its homeostasis, which helps maintain various cellular 
functions, such as: gene transcription (Atar et al, 1995) and post-translational 
protein modification, both of which are very critical for cell viability (Anderson et 
al, 2007, George et al, 2007). Alterations to this fine Ca2+ homeostasis could lead 
to abnormal gene transcription for hypertrophic remodeling, impaired contractile 
function, and arrhythmogenicity.
The cardiac ryanodine receptor (RyR2) is the Ca2+ release channel 
located in the sarcoplasmic reticulum (SR) membrane, and is the central link in 
cardiac EC coupling to control release of SR stored Ca2+, accounting for up to 
90% of total Ca2+ in EC coupling cycle (Bers, 2001). Over the past ten years, 
diastolic Ca2+ leak through dysfunctional RyR2 has been recognized as an 
2important factor contributing to altered Ca2+ homeostasis in heart failure (HF). 
Evidence in several reports shows that abnormality within the RyR2 causes 
increased diastolic Ca2+ leak, leading to contractile and relaxation dysfunction 
(Yano et al 2000; Ai X, et al, 2005; Wehrens et al, 2006). Moreover, the abnormal 
Ca2+ leak through RyR2 could lead to lethal arrhythmia (Wehrens et al 2003). 
Now it is well known that RyR2-mediated SR Ca2+ leak could activate inward 
current through Na/Ca exchanger (NCX) (Vermeulen et al, 1994), and further 
evoke delayed after depolarizations (DADs), which has been proven to be the 
leading reason for ventricular tachyarrhymia and sudden cardiac death (Pogwizd 
and Bers 2004). In HF there is an enhanced diastolic SR Ca2+ leak and other 
changes in electrophysiological substrate (like up-regulation of NCX) that greatly 
enhance the propensity for triggered cardiac arrhythmias (Pogwizd and Bers, 
2002). Approximately 50% of heart failure (HF) patients die of DAD related 
sudden cardiac death (Noseworth et al 2008). All those properties now make 
RyR2 being a potential therapeutic target for anti-HF and anti-arrhythmia. 
A leading hypothesis for explaining the RyR2 dysfunction, enhanced SR 
Ca2+ leakiness in HF and lethal arrhythmias, is defective interaction between the 
N-terminal (N: 0-600) and the central (C: 2000-2500) domains (Yamamoto and 
Ikemoto, 2002). According to this concept, in the resting state, the tight 
interaction between N-terminal and central domains acts as a regulatory switch 
for channel gating activity. This tight interdomain interaction, termed “domain 
zipping” can stabilize the channel in the fully closed state (Yamamoto and 
3Ikemoto, 2002). Weakening of these interdomain interactions may be caused by 
mutations in either the N-terminal or central regions of RyR2 (Uchinoumi et al, 
2010), resulting in an increased opening probability of the RyR2 and leakiness of 
Ca2+. A synthetic peptide (DPc10) corresponding to the central domain (DP2460-
2495) of RyR2, was reported to specifically associate with the N-terminal domain 
competing with its zipping to the central domain, and that the N-domain/DPc10 
association can unzip and destabilize RyR2 (via domain unzipping), to increase 
Ca2+ leakiness (Oda T, et al, 2005).
Calmodulin (CaM) is a ubiquitous and highly conserved Ca2+ binding 
protein which regulates multiple cellular processes. With 148 highly conserved 
residues and ~16.7kDa molecular weight, CaM has two globular Ca2+ binding 
domains with E-F hands, connected by a flexible tether helix (Jurado et al, 1999). 
At high [Ca2+], Ca2+ can bind cooperatively to CaM and result in a conformational 
change that translate intracellur Ca2+ signal to diverse targets. Working as a 
critical regulator for SR Ca2+ release channel, CaM binds to RyR2 
stoichiometrically (four CaMs per tetrameric RyR2). Cryo-EM based 3D RyR 
reconstruction showed that Ca-free CaM (apoCaM) binds to a cleft in the 
cytosolic domain 3 (AA 3614-3643) (Moore et al, 1999; Wagenknecht et al 1994), 
with a distance of 60-70Å to FKBP12.6 on the same side (Cornea et al, 2009; 
Guo T et al 2011). FKBP12.6 was also reported to bind RyR2 tightly as an 
important regulator, but some aspects are still highly controversial (Brillantes AB, 
et al 1994; Marx SO et al 1998; Barg S et al, 1997; Guo T, et al 2010). Mutations 
4(RyRADA) to the highly conserved CaM binding region can severely inhibit CaM 
binding to RyR2 and cause severe hypertrophic cardiomyopathy and early death 
in animal models (Yamaguchi et al, 2007). In a non-ischemic rabbit HF model, 
CaM association to RyR2 was decreased with unchanged total CaM (Ai X, et al, 
2005). A recent study indicates that defective CaM binding to RyR2 is involved in 
catecholaminergic polymorphic ventricular tachycardia (CPVT) associated RyR2 
dysfunction and lethal arrhythmia (Xu X, et al, 2010). All these reports suggest 
that CaM-RyR2 interaction could be a critical molecular substrate for arrhythmias 
and HF pathogenic processes.
Here through FRET (fluorescent resonance energy transfer) detection, we 
for the first time identified RyR2-bound CaM from its numerous binding target 
proteins, and characterized CaM-RyR2 interaction properties in both normal and 
HF cardiomyocytes. The knock-in mice (RyRADA), with genetically disrupted CaM-
RyR2 association while the interaction with other CaM targets are not affected, 
were used to estimate the percentage of Z-line bound CaM that is due to RyR2. 
Furthermore the patho-physiological consequences of CaM for RyR2 regulation 
were defined through function test.
DPc10 has been worked as useful molecular reagents to study RyR2’s 
function and structure. In this study, through fluorescent tagging we can 
characterize the binding kinetics of DPc10 to the RyR2 macromolecular complex 
in the relatively intact environment provided by saponin-permeabilized ventricular 
myocytes. Furthermore, we defined CaM as a critical stabilizer for RyR2 through 
5this RyR2 unzipping peptide and revealed the relationship between CaM and 
RyR2 domains interaction (domain zipping). 
This accomplishment enriched our understanding about RyR2-CaM 
interaction and functional effects on RyR-mediated Ca2+ release in cardiac 
myocytes. This will also expand our knowledge of molecular mechanisms that 
underlie arrhythmogenesis and HF. Importantly, it could pinpoint a potential 
molecular target responsible for Ca2+ triggered arrhythmias and may translate 
into the development of novel therapeutic strategies. 
6CHAPER II 
REVIEW OF RELATED LITERATURE 
Cardiac Excitation – Contraction Coupling 
Cardiac Excitation-contraction coupling (ECC) is an essential physiological 
process in which an electrical stimulus is converted to cardiac contraction, 
resulting in blood being pomped out to meet the need of the whole body. An 
action potential (AP), normally induced by pacemaker cells in Sinoatrial (SA) 
node, can propagate and reach the ventricular myocytes through cardiac 
conduction system (atrial muscle, atrio-ventricular node, His bundle, bundle 
branches and Purkinje fibers). Delivered AP can activate voltage-dependent Na 
channel and produce a very fast upstroke Na current, which brings resting 
membrane potential (Em) from -80 mV up to ~+30-50 mV. Then voltage-
dependent L-type calcium (Ca2+) channels (LTCC) are activated and causing the 
Ca2+ influx, which triggers a subsequent release of Ca2+ stored in the 
sarcoplasmic reticulum (SR). This SR Ca2+ release through the calcium-release 
channels (ryanodine receptors / RyRs), works as a positive feedback response 
and is termed Ca2+-induce Ca2+ release (CICR, Fabiato 1985). As total [Ca2+]i,
released from SR and entered through LTCC, rises to > 100 uM, the free Ca2+
binds to troponin-C (TN-C) that is part of the regulatory complex attached to the 
thin filaments. Once bound with Ca2+, TN-C undergoes a conformational change 
7and exposure of a binding site on the actins for myosin head. The physical 
contact of actin and myosin head results in ATP hydrolysis that supplies energy 
for a slide between the myosin and actin. This sliding shortens the length of 
cardiomycyte and commits the cardiac contraction. Relaxation occurrs after the 
sequestering of cytosolic Ca2+ via SR Ca2+-ATPase (SERCA), sarcolemmal 
sodium-calcium exchanger (NCX), sarcolemmal calcium ATPase and 
mitochondrial Ca2+ uniporter. In mouse ventricular myocytes, ~90% Ca2+ needed 
for contraction is taken up by SERCA back into SR; ~10% Ca2+ is excluded from 
the cell by NCX; < 1% Ca2+ is excluded through sarcolemmal calcium ATPase or 
taken by mitochondrial uniporter (Bers 2001). The lowering of intracellular Ca2+
makes troponin C return to cover the active binding site and to separate myosin 
head from actin, which results in the end of contraction and causing relaxation. 
Cellular Structure Basis of Cardiac EC-Coupling 
1. Myofibrils and sarcomere.  
Muscles are composed of tubular muscle cells (myocytes), and muscle 
cells are mainly (45~60%, Bers, 2001) composed of tubular myofibrils (Fig. 1), 
which is mainly constituted by myosin (thick filament) and actin (thin filament). 
Striated myofibrils, like skeletal and cardiac muscle, are composed of 1.8 um size 
repeating sections of sarcomere that is the fundamental contractile unit (Fig. 1). 
Z-line, where actin molecules (thin filaments) are attached (Fig 1), forms the 
border of the sarcomere (Bers, 2001). 
82. Sarcolemma and transverse tubules.
The sarcolemma is the cell membrane of a muscle cell. In striated 
muscles, the cell membrane invaginates regularly into the cytoplasm of the cell, 
forming a special membranous tubule structure termed transverse tubules (T-
tubules) (Fig. 1). These T-tublues allow a simultaneous penetration of 
sarcolemma depolarization into the interior of the cell for a synchronous Ca2+
release and contraction. In cardiac muscle, T-tubule is typically located at Z-line 
and forms junctional coupling with terminal cisternaes (enlarged bulbous ends of 
the SR at Z-line region), constituting an arrangement called a diad (Fig 1). T-
tubules are the major sites for EC coupling; many essential components, like 
LTCC, RyR, and NCX, are concentrated at the T-tuble region. In the experiments 
named “detubulation”, low osmolarity can disrupt T-tubule. Through detubulation, 
myocyte’s capacitance proportional to the cell surface decreased by ~30% 
(Kawai M, et al, 1999), while ~87% of ICa and almost all NCX current are lost due 
to detubulation (Kawai M, et al, 1999; Yang Z, et al, 2002). With ß-adrenergic 
stimulation, the increase of LTCC current is greater for normal cells than 
detubulated cell, indicating a better coupling of LTCC in T-tubule to the second 
messager than that on the surface of sacolemma (Brette F, et al, 2002; Brette F 
& Orchard C, 2003).
9Z-line Z-lineM-line
Myofibril
Fig 1: Schematic diagram of the mammalian cardiac muscle.
Sarcomere refers to the myofibril between Z-lines. T-tubules are co-locolized 
with Z-lines. Mitochondrias are filled into the zones between Z-lines. 
(Fawcett & McNutt, 1969) 
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3. Sarcoplasmic reticulum (SR).
The SR is an intracellular organelle and the main Ca2+ storage for cardiac 
myocytes. The structure is analogous to the endoplasmic reticulum present in 
other types of cells, with a more regular network structure, specialized for the 
efficient Ca2+ release required for CICR. The SR has a homogenous membrane 
geometry, which can be divided into junctional SR (JSR) and longitudinal SR 
(LSR) (Fig 1). The LSR is distributed throughout the myoplasm and is thought to 
be mostly concerned with Ca2+ uptake. The JSR, which is also called the terminal 
cisternae (Fig 1), exists in close proximity to T-tubules. In junctions between JSR 
and T-tubule, a bridging “foot” structure was found (Franzini-Armstrong, 1970). 
This junctional foot structure turned out to be highly specialized RyRs and 
function as Ca2+ release channels. In the SR lumen, there are three known Ca2+ 
binding proteins: (1) Calsequestrin is thought to bind the majority of Ca2+ in the 
SR and is highly localized to the JSR; (2) histidine-rich Ca2+-binding protein 
(HRC) and (3) sarcalumenin, are distributed throughout the SR suggesting the 
role in LSR Ca2+ buffering (Bers 2004).
Since the SR is a single, physically continuous, and tubular intercellular 
compartment, it was first considered as a homogeneous Ca2+ storage. However, 
with some functional heterogeneity found, this simplistic view is not correct 
(Papps et al, 2003). Now the widely accepted notion is that: physically the SR is 
continuous tubular network and lumenally connected, but it is spatially and 
functionally heterogeneous. This heterogeneity is established by the nonuniform 
11
distribution of SR Ca2+-handling proteins: (1) the main SR luminal Ca2+-buffuer 
proteins, calsequestrin, are mainly in JSR; (2) the Ca2+ uptake pump, SERCA, is 
mainly in LSR; and (3) the SR Ca2+ release channels, ryanodine receptors 
(RyRs), is mainly in JSR (Papp s, et al, 2003). The nonuniform distribution of 
these Ca2+-handling proteins provides the functional division of SR, rather than 
the stuctural divisions (JSR and LSR).  
12
Fig 2: Schematic diagram of monomer RyR2 sequence.
Associated important regulatory proteins and phosphorylation sites are 
indicated on cytosolic side.  6 transmembrane domains form the channel 
core with putative core region GIG. Triadin and Junctin are coupled with 
channel core and linked with calsequestrin (CSQ) (Bers, 2001). 
13
SR Ca2+ release Channel (RyR) 
RyRs, as intracellular Ca2+ release channels, play a central role in 
excitation-contraction coupling (ECC). This channel controls the release of SR 
stored Ca2+ accounting up to 90% total Ca2+ in EC coupling cycle (Bers 2001). As 
a family of Ca2+ release channels found on intracellular Ca2+ store/release 
organelles like SR, RyRs are expressed in many types of cells and three 
isoforms have been identified: RyR1 is primarily in skeletal muscle; RyR2 is the 
main isoform in cardiac muscle; RyR3 is expressed in various tissues at low 
level. In striated muscles, RyR1/RyR2 is concentrated at the Z-line or T-tubule 
region in the packed arrays. In a cardiac junction ( at Z-line or T-tubule), it is 
estimated up to 200 RyRs are packed into 60 – 100 nM diameter circle region for 
a typical cardiac couplon, in which RyR tetramers are connected through corner-
contact and implied an functional coupling for RyRs gating in the couplon (Marx 
et al 2001; Bers, 2001). 
1. RyR structure:   
As the biggest ion channel discovered so far, RyR is composed of four 
monomers that form a homotetramer and comprise a single RyR channel (Bers 
2001). Each monomer has over 5000 amino acids and ~560 kDa molecular 
weight. The majority of the amino acid sequence folds to form the cytoplasmic 
domain, which provides docking sites for most channel regulators like CaM, 
FKBP, Ca2+, kinases and phosphatases. Only a small part of the c-terminal 
sequence forms the transmembrane domain and channel pore (Fig.2), where the 
14
loop between 5th and 6th transmembrane domain (Zhao M, et al, 1999) works as 
a putative pore loop (Fig 2, Bers 2004). 4 pore loops form the narrowest part of 
the channel pore that works as ion selection and mediates Ca2+ passage (Bers 
2004). Triadin and junctin are SR membrane proteins which interact with RyR 
transmembrane domain (Fig 2). Calsequestrin, the major intra-SR Ca2+-binding
protein, linked to triadin and junction in RyR (Fig 2). And three proteins form a 
complex that is thought for the sensation of SR lumenial Ca2+ level and the 
gating of RyR (Caswell AH, et al, 1991; Knudson CM, et al, 1993; Jones LR, et 
al, 1993; Zhang L, et al, 1997).
2. Regulation of RyR 
a. Ca2+, Mg2+, and ATP 
Ca2+ is the charge carrier conducted by RyR in EC coupling; it also works 
for RyR modulation from cytoplamic and SR lumen sides. In single channel 
experiments, cytoplamic Ca2+ shows two-phase regulation for RyR1. Low Ca2+
concentration (1-10 μM) activates RyR1 by binding to specific high-affinity sites; 
high Ca2+ concentration (1-10 mM) inhibits RyR1 by binding to less selective low-
affinity Ca2+ sites (Copello et al., 1997; Meissner 1994; Meissner et al. 1997). 
Cytoplamic Ca2+ is also involved in RyR regulation through CaM and CaMKII 
(reviewed in CaMKII section). For the RyR regulation by Ca2+ from the lumen 
side, it was shown that the increased luminal Ca2+ level can enhance the 
sensitivity of RyR in single channel recording (Györke and Györke 1998; Laver et 
15
al. 2004). The complex of calsequestrin, triadin, and junctin is reported as SR 
luminal Ca2+ sensor to regulate RyR from luminal side (Györke et al. 2004). 
Mg2+ in the physiological concentration works as an inhibitor of RyR, 
probably by binding to the Ca2+ site. Mg2+ is believed to bind to Ca2+ high affinity 
site competitively to reduce opening of RyR; while for low-affinity Ca2+ site, Mg2+
binding presents a direct inhibition (Meissner et al, 1986; Laver et al; 1997).
ATP can activate both RyR1 and RyR2, but differently. Invitro studies 
showed that ATP can activate RyR1 in the absence of Ca2+, but Ca2+ is needed 
for maximal activation (Meissner et al, 1984 and 1986; Laver et al, 2001).  In the 
RyR2 case, the channel can’t be activated by ATP without Ca2+, and ATP can 
sensitize RyR2 to Ca2+ but the effect is smaller than that for RyR1. Considering 
that under physiological conditions most ATP is in a complex with Mg2+, so in cell 
experiments the activation of ATP is mixed with the inhibition of Mg2+ (Lanner et 
al, 2012),  and therefore it is hard to differentiate those effects.
b. FKBP12/12.6 
FKBP12 and FKBP12.6 are also termed as calstabin1 and calstabin2 
respectively.  They physically bind to RyR monomer at the same binding site in 
1:1 manner (Timerman et al. 1993 and 1996). In skeletal muscle, FKBP12 
associates with RyR1 with a relatively low affinity (~1uM) and stabilize the 
channel in the full closed state (Timerman et al., 1996, Brillantes et al., 1994).  
Removal of FKBP12 from RyR1 by pharmacologic depletion or genetic knock-
16
out, can increase channel open probability and prolong channel mean open time 
(Shou et al. 1998; Marx et al. 1998; Ahern et al. 1997). 
In cardiac myocytes, FKBP12.6 preferentially binds to RyR2 with very high 
affinity (Timerman et al. 1993; Guo et al. 2010). Some studies showed that 
FKBP12.6 plays an important role for RyR2 gating to stabilize the channel in a 
fully closed state (Kaftan et al., 1996; Xiao et al., 1997, Xin et al., 2002). By 
contrast, other group’s study challenged this opinion (Timerman et al. 1996, Xiao 
et al. 2007a). The detail for FKBP12.6’s function on RyR2 will be reviewed in 
FKBP section.
c. Calmodulin (CaM)  
CaM binds to RyR monomer in a 1:1 rate (Fruen et al. 2000). As an 
important RyR regulator, CaM regulates RyR1 and RyR2 activity differently and 
Ca2+-dependently. For RyR1, CaM increases the open probability at low 
(<100nM) [Ca2+] but inhibits channel activity at high (>1uM) [Ca2+] (Rodney et al, 
2000). However, for RyR2, CaM inhibits the channel activity at both low and high 
[Ca2+] (Tripathy et al. 1995; Yamaguchi et al. 2005).  Moreover, CaM also can 
regulate RyR indirectly through CaMKII. Details will be further reviewed in CaM 
section.
d. Sorcin 
Sorcin is a 22 kDa Ca2+-binding soluble protein and associates with RyR2 
when Ca2+ is elevated (Meyers et al., 1995; Meyers et al., 1998).  Lipid bilayer 
studies showed that sorcin reduced RyR open probability (Po) and this 
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depression could be relieved by PKA-dependent phosphorylation (Farrell et al., 
2003). In intact myocytes, dialyzing sorcin into the cell can reduce Ca2+ transient 
amplitude with no effect to LTCC current (Farrell et al, 2003).  Furthermore, 
transient over expression of sorcin via adenoviral vector showed a decreased 
Ca2+ transient with the unchanged SR Ca2+ load (Seidler et al., 2003). All the 
studies suggest that sorcin, at high [Ca2+]i, is similar to CaM which inhibits the 
Ca2+ release from RyR2 in Ca2+-dependent manner, but this inhibition can be 
relieved by low Ca2+ and PKA activation.     
e. PKA, CaMKII and phosphatases 
Through muscle A kinase anchoring protein (mAKAP), PKA associates 
with RyR2 at 3003-3039 (Fig. 2) amino acids (Marx et al, 2001).  In the classic 
physiological “fight or flight” situation, sympathetic nervous system (SNS) can 
cause ß-adrenergic stimulation, which results in larger and faster Ca2+ transient 
and consequently stronger and faster muscle contraction.  In this process, the 
activated PKA mainly phosphorlates 4 targets to cause this physiological 
respone: 1. phosphorylation of troponin I decreases myofilament Ca2+ sensitivity 
causing the faster relaxation; 2. phosphorylation of LTCC increases ICa; 3. 
phosphorylation of  phospholamban (PLB) increases SERCA Ca2+ uptake rate 
and SR Ca2+ load; 4, phosphorylation of RyR  alters its gating (Bers 2001).
Regarding RyR, Marx et al found that PKA-dependent RyR 
phosphorylation at Ser-2809 can dissociate FKBP12.6 from the RyR and then 
enhanced single RyR’s open probability in bilayers experiment (Marx et al, 2000; 
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2001).  But other groups found that phosphorylation of RyR by cAMP-dependent 
PKA activation can not cause FKBP12.6 dissociation (Xiao et al, 2004; Guo et al, 
2010). Moreover in PLB knock-out mouse, where SR Ca2+ load can not be 
increased by PLB-phosphorylation, the resting Ca2+ spark frequency, which 
worked as an index for RyR activity, is unchanged with PKA activation (Li et al, 
2002). So another explanation is that the increased Ca2+ spark frequency by 
cAMP is largely due to increasing ICa and SR Ca2+ load by PKA activation (Bers 
2004). Thus the RyR regulation by PKA phosphorylation is still controversial.   
CaMKII is a multifunctional serine/threonine kinase and ? isoform is 
primarily expressed in heart (Edman et al, 1994). CaMKII can co-
immunoprecipitate with RyR2, but the interaction sequence is still not known 
(Zhang et al, 2003). CaMKII has a catalytic domain, a central regulatory domain 
and an association domain.  CaMKII can be activated through Ca2+/CaM binding 
to regulatory domain and displacing the auto-inhibitory domain. Guanine 
nucleotide exchange protein (Epac) and oxidation are also reported to activate 
CaMKII through different pathways (Pereira et al, 2007; Erickson et al, 2008). In 
general, CaM is critical for CaMKII activation. Once CaM/Ca2+ is bound, the 
kinase retains 100% activity. Autophosphorylation can keep 20-80% maximal 
CaMKII activity despite of CaM dissociation (Meyer et al, 1992; Maier et al, 2003) 
CaMKII can modify RyR through phosphorylation at up to 6 sites (Zucchi 
et al, 1997), including Ser-2809 that also is the target for both PKA and PKG 
(Witcher et al, 1991; Wehrens et al, 2004; Rodriguez et al, 2003; Huke and Bers 
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2007). Now Ser2814 is thought exclusively for CaMKII phosphorylation (Wehrens 
et al, 2004).  Most studies on the effect of CaMKII phosphorylation on RyR are 
based on single channel and SR vesicle experiment with mixed results, which 
showed either increased (Wehrens et al, 2004; Hain et al, 1995) or decreased 
channel opening (Lokuta et at, 1995). In intact and permeabilized cells, Bers’ lab 
indicates that CaMKII can increase SR Ca2+ release for a given SR Ca load (Li et 
al, 1997; Guo et al, 2006). However, the data from Wu et al. (2001) showed 
decreased amplitude of Ca2+ transients after CaMKII activation. It could be that 
diasolic SR Ca2+ leak dramatically decreases the SR Ca2+ content and 
secondarily affects Ca2+ transient. So we think that under physiological 
conditions CaMKII phosphorylation exhibits a strong activating effect on RyR 
opening. CaMKII also plays an important pathological role, which is going to be 
reviewed in a later section.
Phosphates, PP1 and PP2a, are reported to associate with RyR2 
indirectly through anchor protein spinophilin and PR130 respectively. The main 
function for phosphatases is to dephosphorylate the phosphorylated RyR2, thus 
keeping the channel in right balance between phosphorylation and 
dephosphorylation (Marx et al, 2001).  PP1 is proposed mainly to 
dephosphorylate both Ser2809 and Ser2814, while Ser2814 is thought to be 
PP2a function site (Huke & Bers, 2008). 
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f. Calsequestrin, Junctin and Triadin 
Calsequestrin (CSQ), as the major intra-SR Ca2+ buffer, works with junctin 
and triadin to form a complex coupled with RyR (Fig 2). As the low-affinity but 
high-capacity Ca2+-binding protein, two type of CSQ isoforms are expressed, 
CSQ1 is in skeletal muscle and CSQ2 is mainly in cardiac muscle. A current 
model hypothesizes that the elevation of luminal Ca2+ weakens the interaction of 
CSQ complex causing SR Ca2+ release to maintain SR Ca2+ content (Zhang et 
al, 1997). Moderate over expression of CSQ can increase SR Ca2+ load and Ca2+
transient amplitude, thereby prolong SR Ca2+ release time (Terentyev at al, 
2003). CSQ2 knockout mouse showed normal SR Ca2+ release and cardiac 
contractility, but exposure to catecholamines can cause an increase in SR Ca2+
leak making this mouse susceptible to catecholaminergic ventricular arrhythmias 
(Knollmann et al, 2006).
g. Caffeine, Ryanodine and Tetracaine 
These three pharmacological compounds are broadly used as exogenous 
modulators for RyR function studies. Caffeine can increase the sensitivity of RyR 
to Ca2+ (Sitsapesan et al, 1990). Low concentration (2-5mM) worked as 
sensitizer for SR Ca2+ release; high concentration (10mM) can completely open 
RyR and is used extensively for evaluation of SR Ca2+ content. Ryanodine, a 
plant alkaloid, binds RyR with high affinity causing bimodal effects. In single 
channel recording, low dosage of ryanodine can increase SR Ca2+ release; high 
concentration of ryanodine can block RyR completely (Meissner, 1986). The 
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binding site of ryanodine is proposed to be the channel pore (Callaway et al, 
1994); it was reported that the diameter of RyR pore could be changed by 
ryanodine binding (Tinker and Williams, 1993; Tu et al, 1994); RyR opening can 
promote ryanodine binding and keep the channel in the open state (Chu et al, 
1990). Tetracaine is a potent local anesthetic, which can bind to RyR in a 
reversible manner. At low concentrations, tetracaine causes an inhibition of SR 
Ca2+ release; while at high concentrations, tetracaine blocks SR Ca2+ release 
completely (Györke et al, 1997) 
Ca2+ Sparks, Ca2+ transients and Ca2+ waves 
The Ca2+ spark is a local increase in the concentration of intracellular Ca2+ 
and regarded as the elementary unit of SR Ca2+ release. It comes from the 
opening of a group of SR Ca2+ release channels (RyRs, 6-20) and the release 
normally does not propagate to surrounding sites (Blatter et al, 1997; 
Lukyanenko et al, 2000). It can be detected with a laser scanning confocal 
microscope and fluorescent Ca2+ indicator (Cheng et al, 1993). A prevailing 
concept stated that the whole cell global Ca2+ release (Ca2+ transient) triggered 
by L-type Ca2+ current is the summation of Ca2+ sparks spatially and temporally 
(Wier and Balke, 1999). When a Ca2+ spark is large enough to activate other 
Ca2+ release channels around through CICR (calcium induce calcium release), it 
can cause a propagation of Ca2+ sparks which is termed as “Ca2+ wave”. A “fire 
diffuse fire” mechanism on the basis of CICR is thought to underlie Ca2+ waves: 
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Ca2+ released during wave propagation at one site by “firing” diffuses to adjacent 
sites (Stern, 1992). Then corresponding rise in Ca2+ concentration induces 
another CICR which is the next firing and carries on the wave (Stern, 1992; 
Keizer et al., 1998). Ca2+ wave is therefore regarded as spontaneous SR Ca2+
release, which is thought the summation of not temporally synchronized Ca2+
sparks. Some studies showed that Ca2+ wave can greatly increase diastolic Ca2+
and then trigger cardiac arrhythmia. 
SR Ca2+ leak 
The SR, as the highly special intracellular Ca2+ store organelle, contains ~ 
1mM free Ca2+ and ~ 2.7 mmol/L total Ca2+ (Shannon and Bers, 1997; Shannon 
et at, 2003), while the diastolic cytosol [Ca2+] is 50-100nM. Due to this large 
chemical driving force, there is a silent efflux of Ca2+ from SR to cytosol under 
resting conditions, which is termed as “SR Ca2+ leak” (Gomez et at, 1996; Zalk et 
al, 2007). This Ca2+ leak is primarily mediated by RyR and can be detected in 
intact cell through Ca2+ sparks, which indicate a local Ca2+ increase by ~200nM 
within 2 um spatial diameter and last about 50 ms (Bers, 2001; Cheng et al, 
1993).  These irregular and spontaneous leak events, as a comparison to 
synchronized SR Ca2+ release (Ca2+ transient) by stimulation, are only defined to 
happen in resting condition. Although Ca2+ spark is well-established intracellular 
local SR Ca2+ release event in cardiomyocytes, in adult mammalian skeletal 
muscle this phenomenon is rarely observed. The reason could be the property of 
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RyR1, which is activated very differently through physical interaction between L-
type Ca2+ channel and RyR1, not through CICR. This section is going to focus on 
cardiac myocytes SR Ca2+ leak. 
Under physiological condition, the normal SR Ca2+ leak helps maintain 
various cellular functions, such as: 1, gene transcription, a process termed as 
excitation-transcription coupling (ETC) (Atar et al, 1995); 2, post-translational 
protein modification, a process very critical for cell viability (Anderson et al, 2007, 
George et al, 2007); 3, enhancing local regenerativity and reliability of CICR 
(Keller et al, 2007; Lindegger et al, 2005); 4, protection by preventing SR Ca2+
overload in some extreme condition like ß-adrenergic over-stimulation (Yang et 
al, 2007). Although Zima et al (2010) indicated importance of non-spark-
mediated leak and that a complete block of RyR2 can’t totally abolish the leak in 
physiology condition, RyR2 mediation is still regarded as the major pathway for 
SR Ca2+ leak. RyR2 is normally closed at resting state under low cytosolic 
diastolic Ca2+ (~50-100nM). But in pathological states like heart failure and 
CPVT, due to pathogenetic modification on RyR2, there is a dramatically
enhanced SR Ca2+ leak, primarily mediated through RyR2 (Shannon et al, 2003; 
Maier et al, 2003; Ai et al, 2005; Kohlhaas et al, 2006; Lehnart et al, 2006; 
Curran et al, 2007). The patho-physiological role of SR Ca2+ leak can work as 3 
primary causes for progressive deterioration in cardiac function: 1, increased SR 
Ca2+ leak can work as abnormal Ca2+ signal which is involved in directly inducing 
gene transcription leading to hypertrophic remodeling (Frey et al, 2000; Wu et al, 
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2006; Molkentin et al, 2006; Mckinsey et al, 2002). 2, Increased SR Ca2+ leak 
combined with reduced SR Ca2+–ATPase (SERCA) in HF (Bers, 2001), can 
predominantly reduce SR Ca2+ load and impair contractile function(Houser et al, 
2000; Pogwizd et al, 2001).  3, Increased SR Ca2+ leak could activate inward 
current through Na+/Ca2+ exchanger (Vermeulen et al, 1994), and further evoke 
delayed after depolarizations (DADs) and arrhythmogenicity (Pogwizd and Bers 
2004; Shannon et al, 2003). All these properties now make RyR2 mediated SR 
Ca2+ leak a potential therapeutic target for anti-HF and anti-arrhythmia.
Main mechanisms for enhanced SR Ca2+ leak
1. FKBP12.6 dissociation by PKA phosphorylation 
This hypothesis was first proposed by Marx and colleagues (Marx et al, 
2000). There are two main supportive points for this theory: (1), FKBP12.6 is the 
main stabilizer to keep RyR2 in a fully closed state, and (2), RyR2 
hyperphosphorylation at Ser2808 by PKA can dissociate FKBP12.6 from RyR2 
causing a leaky state. One of the main features for HF is the chronic 
hyperadrenergic state, causing a relatively high plasma catecholamine level and 
ß-adrenergic over stimulation. Then PKA can be chronically over activated in a 
cAMP-dependent pathway and hyperphosphorylate RyR2 at Ser2808 to 
dissociate FKBP12.6 (Marx et al, 2000). Once in the hyperphosphorlated state 
that means 3-4 of 4 monomers are phosphorylated, RyR2 loses FKBP12.6 
association and could not close completely. So that RyR2 is sensitized to 
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cytosolic Ca2+ leading to an enhanced open probability and diastolic SR Ca2+
leak (Lehnart et al, 2004). PKA hyperphosphorylation / FKBP12.6-depletion 
theory is supported by other studies about cAMP-specific PDE4D3, a local 
phosphodiesterase that could decrease cAMP though negative feedback (Lehart 
et al, 2005); PDE4D3 dissociation from RyR can cause elevated cAMP for 
chronic activation of PKA and RyR hyperphosphorylation. In some HF models, 
RyR2 complex is also found less associated with phosphatases (PP1, PP2a), 
which can decrease RyR2 dephosphorylation rate and keep the balance in favor 
of hyperphosphorylation (Reiken et al, 2001). Some knock-in mouse model 
studies also provide support for PKA hyperphosphorylation theory. In RyR2-
S2808A knock-in mouse, RyR2 can’t be phosphorylated at Ser2808 and 
FKBP12.6 dissociation upon PKA activation is not observed. In post-myocardial 
infarction (MI) HF model, RyR2-S2808A mice exhibit stronger resistance to the 
progression of HF than wild-type (WT) mice (Wehrens et al, 2006).  PDE4D3 
knock-out mice also showed cardiomyopathy with hyperphosphorylated RyR2 at 
Ser2808 and FKBP12.6 depletion (Lehnart et al, 2005). Furthermore, the direct 
genetical depletion of FKBP12.6 showed that this mouse had an increased 
propensity for exercise-induced ventricular tachycardia (Wehrens et al, 2003). 
But in the past 10 years, this mechanism also met challenges constantly 
from other groups for both two main supporting points, focusing on whether PKA-
mediated hyperphosphorylation at Ser2808 could dissociate FKBP12.6 from 
RyR2 and whether FKBP12.6 binding could alter RyR2 gating. Jiang et al (2002) 
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found that, in human and canine failing heart, FKBP12.6 exhibits unchanged 
binding affinity to hyperphosphorylated RyR2, compared with that from non-
failing heart. In a recent paper, through direct measurement of binding affinity in 
permeabilized cardiomyocytes, PKA phosphorylation of RyR2 did not change 
binding properties between FKBP12.6 and RyR2 (Guo et al, 2010); the same 
study also showed that saturating RyR2 with FKBP12.6 only provides a mild 
RyR2 inhibition (~20%), suggesting a small relevance for RyR2 regulation in 
cardiomyocytes. Moreover, FKBP12.6 knock-out mice failed to demonstrate 
increased arrhythmia propensity by the combination of epinephrine and caffeine, 
which is the classical method to induce over SR Ca2+ leak (Xiao et al, 2007). 
Knock-in mice (RyR2-S2808A), where RyR2-2808 is nonphosphorylatible, are 
supposed to provide cardio-protection for PKA phosphorylation. But this knock-in 
mouse failed to produce relevant cardio-protective function to prevent HF 
development and progression both in the MI (myocardial infarction) and thoracic 
aortic constriction HF animal models (Berkusky et al, 2007; Zhang & Houser, 
2012). Piece above information together, PKA hyperphosphorylation and 
FKBP12.6 dissociation mechanism is still highly controversial.
2. CaMKII and CaMKII phosphorylation 
CaMKII attracted tremendous interest over the last decade in the cardiac 
field, because it is broadly involved in ETC and ECC in the heart. In this section, I 
am going to briefly review the impact of CaMKII on the whole cardiac system, 
especially on ETC and ECC. CaMKII? is the predominant isoform in heart with 
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two subtypes: ?B (with a nuclear localization signal [NLS]) localized to nucleus 
and ?C localized to the cytosol (Maier et al., 2003). CaMK ?B has been reported 
to be broadly involved in ETC through its modulation of gene expression via 
different transcription factors (Zhang and Brown, 2004). For cardiac hypertrophic 
growth and gene expression, the Gq/PLC/InsP3 signaling pathway is extensively 
studied. In this signaling pathway, NE, PE or ET-1 could affect the expression of  
atrial natriuretic peptide (ANF), brain natriuretic peptide (BNP), myosin light 
chain-2 (MLC-2), and ?, ß-myosin heavy chain (Anderson, Brown & Bers 2011).  
The hypertrophy, caused by those fetal gene expressions, could be prevented by 
CaMKII inhibition in neonatal rat ventricular myocytes (Zhu et al, 2000; Ramirez 
et al, 1997).  CaMKII also can alter cardiomyocyte hypertrophic gene expression 
through HDACs and MEF2 signaling. Phosphorylation of class II HDACs 
mediated by CaMKII can interrupt MEF2-HDAC interaction resulting in HDAC 
nuclear export while free MEF2 for the activation of downstream hypertrophic 
gene transcription (Berger et al, 2003; Frey et al, 2000). CaMKII?c is also 
reportly involved in the cardiomyocyte apoptosis via the mitochondria-dependent 
pathway. Increased CaMKII?c activity enhances RyR2 mediated SR Ca2+ leak 
and consequently affect mitochondrial Ca2+ and further impacts on expression of 
p53 and the pro-apoptotic BAX protein (Zhu et al, 2003 & 2007; Toko et al, 
2010). In HF, there is an upregulation of NCX, whose enhanced expression by 
ISO was thought had a link to the activation of CaMKII and transcription factor 
AP-1 (Mani et al, 2010).
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In ECC, multiple proteins are regulated by CaMKII, including: L-type Ca2+
channel, phospholamban, RyR2, Na and K channels.  CaMKII phosphorylates L-
type Ca2+ channel causing a positive staircase of ICaL, representing an increase of 
ICa amplitude and prolonged LTCC inactivation over a series of pulses (Yuan et 
al, 1994; Xiao et al, 1994). This phenomenon is termed as Ca2+-dependent ICaL
facilitation. Moreover CaMKII?c can cause modifications of Na channels and shift 
the channel availability to more negative membrane potentials, which means 
more Na channels can be activated in intermediate inactivated sate (Wagner et 
al 2006). This can produce Brugada syndrome like effects (Bers and Grandi 
2009). CaMKII also enhances late non-inactivating INa, linked with ischemia / 
reperfusion injury, HF and long QT syndrome 3 (LQT3). For K channels, CaMKII 
modification can slow transient outward K current (Ito) and accelerate their 
recovery from inactivation, both of which can shorten AP duration and refractory 
period (Tessier et al, 1999). Over expression of CaMKII is reported to induce 
down-regulation of inwardly rectifying IK1, which stabilizes the resting membrane 
potential. The reduction of IK1 can increase excitability (Wagner et al, 2009). 
Phosphorylation of PLB on Thr-17 by CaMKII can cause a release of PLB 
inhibition of SERCA, enhances SR Ca2+ uptake and increases SR load (Mattiazzi 
et al, 1994). In HF, the expression and activation of CaMKII are reportedly 
increased, resulting in increased RyR2 phosphorylation and diastolic SR Ca2+
leak (Ai et al, 2005). The wildly accepted view is that, RyR2 phosphorylation at 
Ser2814 by CaMKII activates RyR2 gating during both diastole and systole (Bers 
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& Grandi 2009; Wehrens et al, 2004; Li et al, 1997; Guo et al, 2006). In a knock-
in mouse of RyR2-S2814D to mimic the RyR2 hyperphosphorilation by CaMKII, 
the mutation caused a significantly enhenced diastolic SR Ca2+ leak and 
demonstrated increased arrhythmia propensity. While RyR2-S2814A mutants, 
where RyR2 can’t be phosphorylated at Ser2814 by CaMKII, shows resistance to 
ISO induced arrhythmia (Van Oort et al, 2010). Taken together, it is well 
accepted that CaMKII mediated RyR2 Ca2+ leak is one of the major 
arrhythmogenic reasons in HF (Chelu et al, 2009).
3. Store Overload Induced Ca2+ Release (SOICR)
Chen and colleagues first proposed this concept based on a phenomenon: 
spontaneous Ca2+ release, which is the SR Ca2+ release in absence of 
depolarization activating L-type Ca2+ channel (Fabiato et al, 1983; Jiang et al, 
2004). Spontaneous Ca2+ release can be observed cellularly in the form of Ca2+
wave, causing a dramatically local and global cytosolic Ca2+ increase. Combined 
with NCX, Ca2+ waves can trigger transient inward current and produce DADs. 
When the amplitude of DAD reaches the threshold for Na chanel activation, an 
action potential can be triggered, leading to triggered arrythmias (Bers 2001; 
Pogwizd & Bers 2004). Spontaneous Ca2+ release has a strong dependence on 
the Ca2+ load of SR. Some conditions, such as: ß-adrenergic stimulation, digitalis 
toxicity, elevated extracellular Ca2+ concentration, and fast pacing, lead to an 
increase in SR Ca2+ content  to an overload state which can subsequently cause 
inappropriate Ca2+ “spillover” (spontaneous Ca2+ release) during diastole. And 
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this was termed as store overload-induced Ca2+ release (SOICR) (Xiao et al, 
2007).
Since SOICR exhibits a strong link to SR Ca2+ load, it is suggesting that 
luminal Ca2+ concentration is the most important trigger for this spontaneous SR 
Ca2+ release. This is very different with the CICR, where the cytosolic Ca2+
underlies the activation of RyR2. So the sensor regulating SR Ca2+ release 
according to SR luminal Ca2+ is proposed to set a threshold for SR Ca2+ release 
(Ching et al, 2000). Diaz et al, (1997) found Ca2+ wave occurring at the threshold 
of SR Ca2+ load of ~100 μmol/L cytosol, which is similar to the normal SR Ca2+
content (1~1.5 mmol/L) because SR volume is 18 times smaller than that in 
cytosol (Bers 2001). A SR Ca2+ release by Ca2+ wave could decrease SR Ca2+
load by ~15 μmol/L cytosol, which makes SR Ca2+ load fall below threshold 
(Bers, 2001). Evidence supports the proposition that activation of RyR2 is 
mediated by a luminal Ca2+ sensor that is distinct from cytosolic Ca2+ sensor, but 
the molecular identity of this luminal Ca2+ sensor is not yet identified.
Both RyR2 and CASQ2-complex are proposed as primary luminal Ca2+
sensor, and mutations on RyR2 and CASQ2 cause CPVT, characterized by 
increased SR Ca2+ leak and DAD triggered arrhythmia. So CPVT provide a very 
good model for SOICR study. In Chen’s model, with normal RyR2, the threshold 
for SOICR is higher than the free luminal [Ca2+], even in SR Ca2+ overload 
condition, so there is none or little Ca2+ spillover. The CPVT mutation in RyR2 
can lower the SOICR threshold, but which is still higher than resting luminal Ca2+
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level while below the level of SR Ca2+ in overload state. Thus the increased free 
Ca2+ in SR to the overload state, due to catecholamine stress or digitalis 
application, can exceed the lowered threshold causing SOICR, while in basal 
resting state this will not happen (MacLennan & Chen 2009).  For mutations on 
CASQ2, two hypothesises are proposed. (1), the mutations, like R33Q or the 
reduction of CASQ2, could lower SOICR threshold and sensitize SR Ca2+ release 
channel to luminal Ca2+ with the similar effect as RyR2 mutation. (2), the mutation 
could reduce the level of CASQ2 and/or Ca2+ buffering capability; this means 
that, for the same total Ca2+, the free Ca2+ could be much higher to exceed the 
normal SOICR threshold and thereby lead to Ca2+ spillover.
In the bilayer experiments, where the sensitivity of RyR2 to luminal Ca2+
can be gauged, Jiang and colleagues identified some RyR2 mutations that 
showed a consistent behavior characterized by an enhanced response of the 
channel to luminal Ca2+ activation (Jiang et al, 2004 & 2005). Those mutations 
are: L433P and R176Q/T2504M located in the N-terminal region of the channel; 
mutations S2246L and R2474S located in the central region; and Q4201R, 
N4104K, R4496C, I4867M, N4895D, and V4653F58 located in the C-terminal 
region. In summary, SOICR described an aspect of SR Ca2+ leak, the 
spontaneous Ca2+ release (Ca2+ wave); the most important consequence is DAD 
and triggered arrhythmia; the main reasons for SOICR are RyR2 sensitization to 
luminal Ca2+ and enhanced SR Ca2+ load.
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4. Reduction / oxidation (Redox) Modification 
The heart is an obligate aerobic organ with the highest oxygen 
consumption in the body (Giordano, 2005). As the myocardial O2 level is low, 
hypoxia or ischemia could lead to an increased production of redox-active 
molecules, which can work as both a benevolent and dysfunctional role to 
cardiac system. Redox-active molecules, mainly including reactive oxygen 
species (ROS) and reactive nitrogen species (RNS), are widely characterized for 
their important role in the cardiac pathologies, especially in ischemia-reperfusion 
injury (Zima & Blatter 2006). ROS are the natural byproducts from normal 
metabolism of oxygen, which consist of hydroxyl radical (OH.), superoxide (O2-)
and hydrogen peroxide (H2O2). In hypoxia, ROS level can increase dramatically, 
therefore cause significant oxidative damage to the cell, which is known as 
oxidative stress. Reactive nitrogen species (RNS) are a family of active 
molecules mainly derived from nitric oxide (NO) metabolism. Peroxynitrite 
(ONOO?) is the main active component and has significant effects with various 
biological targets (Khan et al, 2004). Both ROS and RNS can cause protein 
alternations mainly by cysteine oxidation. Therefore, in protein oxidative 
modification, these two species of redox-active molecules are often collectively 
referred to as ROS/RNS. Catalase, glutathione peroxidase and superoxide 
dismutase (SOD) are known as the main defense system against this oxidative 
damage.
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With 20 active cysteines that could be sensitive to redox modification per 
subunit, RyR is a well established redox-modulation channel. Mainly, 3 
modifications by redox-active molecules could happen to RyR: (1), the oxidation 
through disulfide crosslinking: reagents specifically oxidize two spacially closed 
free SH groups and promote the formation of disulfide bonds between two 
cysteines within RyR (Eager et al, 1997; Haarmann et al, 1999; Xia et al, 2001); 
(2), S-nitrosylation which is the addition of a nitroso group to a sulfur atom of an 
amino acid, and (3), S-glutathionylation, the addition of a glutathione molecule to 
the amino acid through a disulfide linkage (like protein-SSG). Normally 
modifications by low concentration of ROS/RNS are reversible, while high level of 
ROS/RNS is able to cause irreversible modifications leading to defective 
channels (Ferdinandy and Schulz 2003). In RyR1 several specific cysteines are 
already identified for redox-modulation. Cys36 and Cys315 are located at N-
terminal region and clamp domain (Liu et al, 2005; Hamilton and Serysheva; 
2009 Amador 2009). Cys3635 is located in subdomain 3 which is primary CaM 
binding region (Moore et al, 1999; Sun et al, 2001), and S-nitrosylation of 
Cys3635 was showed to activate RyR1 by abolishing CaM’s inhibition (Moore et 
al, 1999). Oxidized glutathione (GSSG) also shows the ability to increase 
channel activity by dissociating CaM binding from RyR2 (Balshaw et al, 2001). 
Pathologically, high level nitrosylation to RyR1 has been reported in muscle 
dystrophy, and is thought to contribute to muscle weakness by increased SR 
Ca2+ leak (Bellinger et al, 2009). For RyR2, the main modification by ROS/RNS is 
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oxidation. Those modifications are believed to cause defective RyR2 and 
increase SR Ca2+ leak in chronic HF (Terentyev et al, 2008; Belevych et al, 
2009). Unlike in RyR1, the specific redox-sensitive cysteine residues on RyR2 
have not been identified. Another modification by ROS/RNS is S-nitrosylation 
modification, in which S-nitrosoglutathione is required (Sun et al, 2008). Notably, 
the high reactive free radicals (like OH. and O2) only have very limited diffusion 
range which is within nanometers (Haugland RP, 1996). This implies that ROS 
modification would be predominantly proximal effect and highly 
compartmentalized (Zima & Blatter 2006). 
5. The interruption of interdomain interaction 
Based on the studies about RyR1 and RyR2 related mutations, Ikemoto 
and Yamamoto (2002) first proposed this inter-domain interaction concept. Miss-
sense mutations on RyR1 and RyR2 have been found related with two human 
inherited diseases: catecholaminergic polymorphic ventricular tachycardia 
(CPVT) and malignant hyperthermia (MH) (Brini 2004). The pattern of all known 
mutations on RyR is not a random distribution but clustered into 3 major regions: 
N-terminal domain (1-600 amino acids), central domain (2000-2500 amino acids) 
and channel core forming region (C-terminal domain, 4000-5000 amino acids). 
Mutations at either N-terminal or central regions seem to result in similar 
sensitization of Ca2+ release channel and leakiness, so they proposed an inter-
domain interaction concept: after protein folding, N-terminal domain and central 
domain could get close in 3D structure and interact with each other to act as a 
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regulatory switch for channel-gating. A tight interaction between two domains 
serves to stabilize the channel in the full closed “zipping” state; a mutation in 
either domain can weaken this inter-domain interaction and cause the channel in 
the “unzipping” state (Fig 3b), resulting in channel hypersensitivity and Ca2+
leakiness (Yano & Matsuzaki 2005).
To prove this theory, some synthetic domain peptides are developed for 
inter-domain unzipping. In RyR1, DP4 corresponding to the Leu2442–Pro2477 in 
central domain, was shown to increase RyR1 open probability by enhanced [3H]-
ryanodine binding and further induced Ca2+ release from the SR vesicles 
(Yamamoto et al, 2000). DP4 also can increase the frequency of Ca2+ sparks in 
skinned skeleton fibers, and open probability of RyR1 in bilayer experiment 
(Shtifman et al, 2002). The proposed mechanism is that DP4 can insert into the 
zipped domain pair causing domain unzipping and channel leakiness (Fig 3b). A 
similar cardiac-domain peptide (DPc10) is also synthesized, corresponding to the 
Gly2460–Pro2495 in the central domain of RyR2 (Yamamoto and Ikemoto 2002). 
DPc10 has been shown to produce significant activation of the RyR2 at low Ca2+
concentrations, which is similar as DP4’s effect to RyR1 (Yamamoto and Ikemoto 
2002). In pathological canine HF model induced by rapid RV pacing, Oda et al 
(2005) showed the domain unzipping and abnormal Ca2+ leakiness in HF; 
furthermore they suggested a possible link between domain unzipping and 
FKBP12.6 dissociation. They hypothesized that, in the DPc10-induced domain 
unzipping model, the domain unzipping can facilitate both cAMP-dependent 
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RyR2 hyperphosphorylation and FKBP12.6 dissociation (Oda et al, 2005). 
However, DPc10 induced domain unzipping and SR Ca2+ leaking could happen 
with no change to RyR2 phosphorylation and RyR2-bound FKBP12.6 (Oda et al, 
2005), which revealed no or weak relation between domain unzipping and 
FKBP12.6 binding. Although the relation between PKA phosphorylation / FKBP 
dissociation and domain interaction are still not clear, Yano and colleagues think 
the domain unzipping is the key mechanism for the destabilization of RyR2 and 
Ca2+ leakiness (Yano M, 2006).
With an insertion of green fluorescent protein (GFP) into defined position 
in the primary amino acid sequence and followed difference mapping, Liu et al 
(2005) showed a physical proximity between N- and central domains in the 3D 
structure of RyR2.  They also find FRET interaction between these two regulatory 
domains in HEK cell with CFP/YFP labeled N- and central domains, However, 
the zipping pair (N- and central domains) is not from the same monomer but from 
neighbor RyR2 subunits. The treatment of DPc10 (Fig 3c) or caffeine-ryanodine 
(Fig 3a) can decrease the FRET interaction causing the unzipping condition in 
the visualized method; dantrolene, the effective medication for MH caused by 
RyR1 mutation, can prevent the domain unzipping caused by DPc10 insertion 
(Liu et al, 2010).
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Fig 3: Domain unzipping. a, domains, in the tightly zipping state, was 
unzipped through agonists like high Ca2+ and caffine + ryanodine. b, unzipping 
by CPVT mutation. c, unzipping by synthetic domain peptide DPx. (Ikemoto  
2002).
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Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) 
CPVT, a primary electrical myocardial disease without structural cardiac 
abnormalities, is characterized by exercise and stress related ventricular 
tachycardia which may lead to ventricular fibrillation and sudden death (Priori SG 
& Chen SR, 2010). It is thought to affect as many as one in ten thousand people, 
and to cause as high as 15% of all unexplained sudden cardiac deaths in young 
people (Guy Katz et al, 2009). Bidirectional tachycardia, which is a ventricular 
arrhythmia with a 180º alternation for QRS axis (in EKG) on a beat-to-beat basis, 
is considered as a typical diagnostic marker for CPVT (Coumel P, et al, 1978; 
Priori SG, et al, 2001). But some individuals also have polymorphic VT instead of 
a "stable" QRS axis alternation. Mutations on the genes encoding RyR2 and 
CASQ2, are currently known to cause CPVT (Priori SG, et al, 2001; Lahat H, et 
al, 2001). It is accepted that CPVT requires a synergy between a genetic defect 
(i.e., mutation) to sensitize SR Ca2+ release channel, and an external stimulus 
(i.e., stress or exercise) which can dramatically increase the SR Ca2+ content for 
SR Ca2+ leak. All these conditions working together lead to aberrant Ca2+ 
release, which consequently activates NCX’s function, generating transient 
inward currents and triggering arrhythmias. 
CPVT1 is caused by mutations on RyR2 in the autosomal-dominant form. 
Now 82 mutations are reported to cause CPVT1; 79 are point mutations and 3 
are small deletion/insertion (Priori & Chen, 2010). Those mutations are 
considered to confer RyR2 an abnormal gain of function, assumed to cause 
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spontaneous Ca2+ release due to altered sensitivity to luminal Ca2+ or / and 
cytosolic Ca2+, or increased response to phosphorylation by sympathetic agonist 
(Priori & Chen, 2010; Guy Katz & Michael, 2009). These mutations are not 
evenly distributed across the entire RyR2 coding region, but clustered into well 
defined domains: domain I (amino acid 77 to 466), domain II (amino acid 2246 to 
2534), domain III (amino acid 3778 to 4201), domain IV (amino acid 4497 to 
4959) (Guy Katz & Michael, 2009). Two mechanisms are proposed for CPVT1. 
The First one is FKBP12.6 related; Wehrens et al (2003) first hypothesized that 
CPVT mutations could impair FKBP12.6 binding to RyR2 and cause channel 
leaking. In bilayer experiments for some CPVT1 mutations on central region 
(S2246L, P2328S, R2474S) and C-terminal region (Q4201R, R4494C, V4653F), 
they found a common decreased affinity of FKBP12.6 to RyR2 with any those 
mutation (Wehrens et al, 2003; Lehnart et al, 2008). However, some studies 
found different results that CPVT1 mutations had no effect on FKBP12.6 binding 
(Jiang et al, 2005; George CH et al, 2003). So both in HF and CPVT, the role of 
FKBP12.6 is highly controversial, at least it won’t be considered as the sole 
causative reason for all CPVT1 mutation (Priori & Chen, 2010). The other 
alternative mechanism is the so called “domain unzipping” proposed by Ikemoto 
and Yano, which was supported by recent RyR2 3D structure study (Amador FJ, 
et al, 2009; Lobo PA, et al, 2009; Tung CC, et al, 2010), indicating that most 
CPVT mutations are located on the interface of domains where domain-domain 
interaction could be disrupted.
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Mutations in the gene for cardiac calsequestrin isoform 2 (CASQ2), can 
cause an autosomal recessive form of CPVT (CPVT2). 8 missense mutations are 
reported until now. R33Q and D307 are first reported to reduce the level of 
CASQ2 to 5% and 45% respectively (Rizzi N, et al 2008; Song L, et al 2007); 
along with other missense mutations (K206N, L167H), those four were also 
showed to decrease the Ca2+ binding capacity or/and Ca2+–dependent 
polymerization of CASQ2 (Rizzi N, et al 2008; Bal NC, et al, 2010; Kirchhefer U, 
et al 2010; Valle G, et al 2008). With the same amount of total Ca2+, reduced SR 
Ca2+ buffering will result in a fast SR fill-up of free Ca2+ during diastole and 
potentially higher level of SR free Ca2+. Both conditions can increase the 
propensity for SOICR and consequently DAD. Beside the reduction of SR Ca2+
buffering capacity, R33Q alters RyR2 sensitivity to luminal Ca2+ lowering the 
threshold for SR Ca2+ spontaneous release (Qin J, et al 2008; Terentyev D, et al 
2008). However, since CASQ2 works as the major intra-SR Ca2+ buffer, the 
reduction of CASQ2 protein and Ca2+ buffering capacity is thought the main 
mechenism for CPVT2 muatation (Knollmann BC, 2009). 
Calmodulin
Calmodulin (CaM) is a ubiquitous and highly conserved Ca2+ binding 
protein which regulates multiple cellular processes, such as channel gating, Ca2+
release, and cell cycle progression. With 148 highly conserved residues and 
~16.7kDa molecular weight, CaM has two globular Ca2+ binding domains with E-
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F hands, connected by a flexible tether helix (Jurado, Chockalingam & Jarrett, 
1999). At high [Ca2+], Ca2+ binds cooperatively to CaM and results in a 
conformational change that translate intracellular Ca2+ fluctuation signal to 
diverse targets, including more than 30 different target proteins, such as: 
phosphodiesterase (PDE), myosin light chain kinase (MLCK), protein 
phosphatase calcineurin (CaN), adenylyl cyclase (AC), nitric-oxide synthase 
(NOS), Ca2+-activated potassium channels, Ca/CaM-dependent kinase (CaMK), 
L-type Ca2+ channels (LTCC) and RyRs (Means et al, 1991; Vogel et al, 1994; 
James P, et al; 1995; Jurado, Chockalingam & Jarrett, 1999; Maier & Bers, 
2002). CaM is widely involved not only in EC-coupling by L-type Ca2+ channel 
inactivation (Zuhlke et al, 1999; Peterson et al, 2000) and RyR2 regulation, but 
also in ET-coupling for hypertrophic signaling transduction especially mediated 
through CaMKII. The total cellular CaM concentration is in the range of 2-25 μM, 
which varies according to different tissues and species (Kakiuchi et al, 1982).  In 
cardiomyocytes, the total CaM is about 2-5 μM depending on the species (Maier 
2006). It was estimated that, in resting conditions, ~90-95% cellular CaM is 
bound to target protein, and free CaM concentration is about 50-75 nM (Wu et al, 
2006)
CaM binds to RyR2 stoichiometrically (four CaMs per tetrameric RyR2), 
and works as a critical regulator for SR Ca2+ release. The primary CaM binding 
region on RyR2 is the residues 3583-3603 (Yamaguchi et al 2003). CaM binds to 
RyR in a Ca2+-dependent way. It is proposed that CaM can switch between two 
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binding positions on RyR due to oscillating intracellular Ca2+ concentration 
(Jurado, Chockalingam & Jarrett, 1999; Samso et al, 2002). However, this 
position switch can not be found by FRET measurements (Cornea et al, 2009; 
Guo et al, 2011). Mutations to highly conserved CaM-binding region on critical 
residues can nearly abolish CaM binding to RyR2. Meissner group bioengineered 
a knock-in mouse in which three amino acids in CaM binding region are mutated 
(RyR2-w3587A/L3597D/F3603A). This triple-mutation greatly impairs CaM 
binding to RyR2 is greatly impaired without interference to other CaM signaling 
pathways and lead to severe hypertrophic cardiomyopathy at early stage 
(Yamaguchi et al, 2007).  In Cryo-EM based 3D RyR reconstruction, Ca2+-free
CaM (apoCaM) binds to a cleft in the cytosolic domain 3 (AA 3614-3643) (Moor 
et al 1999; Wagenknecht et al 1994),  with a distance of 60-70Å to FKBP12.6 on 
the same face of RyR2 (Cornea et al, 2009; Gao et al, 2011). For the functional 
meaning, CaM association can inhibit RyR2 activity both for single channel 
recording and permeabilized cells. It was reported that CaM could stabilize the 
RyR2 in closed state during diastole and could facilitate the termination of Ca2+
release by decreasing the probability of channel reopening, thereby prolonging 
the closed time in bilayer experiment (Xu et al, 2004). In permeabilized 
cardiomyocytes, increasing CaM binding to RyR2 can decrease Ca2+ spark 
frequency by ~70% (Guo et al 2006). In the non-ischemic HF model, CaM 
binding affinity to RyR2 and associated CaM was decreased without changing 
total CaM, and increasing CaM association to RyR2 can reduce SR Ca2+ leak in 
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HF cardiomyocytes (Ai et al, 2005; Ono et al 2010). A recent study indicates that 
defective CaM binding to RyR2 is involved in CPVT-associated RyR2 dysfunction 
(Xu et al, 2010). Taken together, all these reports suggest that CaM-RyR2 
interaction could be a critical molecular substrate for arrhythmias and HF 
pathogenic processes.
FK-506 Binding protein
FKBP is a family of intracellular protein named for its binding to 
immunosuppressant FK506. Two isoforms of FKBP are expressed in the heart, 
FKBP12 and FKBP12.6 (~12 kDa and 108 residues). They are very similar in 
sequence (85% homology, 18 residues different) and 3-D structure (Standaet RF 
ea al, 1990; Lam E et al, 1995). The main structure of FKBP12/12.6 consists of a 
large antiparallel five-stranded, amphiphilic ?-sheet which wrapped with its 
hydrophobic face against an amphiphilic ?-helix, and thus forms a well-ordered 
hydrophobic core, providing a binding site for FK506/Rapamycin (Van Duyne et 
al, 1993; Griffith et al, 1995; Huse et al, 1999). Residues 81 to 96 in 
FKBP12&12.6 form a small flexible subdomain that interacts with FK506 and 
other target proteins (Huse et al 1999; Ke et al 2003). FKBP12 and 12.6 were 
found to associate with RyRs primarily and stoichiometrically (i.e., 4 FKBP: 1RyR 
tetramer / 1 FKBP12: 1 RyR monomer) (Timerman et al, 1993 & 1996). Guo et al 
(2010) described FKBP binding kinetics in permeabilized cardiac myocytes. 
FKBP12.6 preferentially binds to RyR2 with very high affinity (Kd=~1nM), while 
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FKBP12’s binding affinity is much lower (Kd=~200nM). However, the expression 
of FKBP12.6 in mouse cardiac mycytes is low, so that only 10-20% of RyR2s are 
associated with FKBP12.6, and the remaining RyRs are associated with FKBP12 
(Guo et al, 2010).
The function for FKBP12/RyR1 interaction is well understood, with some 
consensus that FKBP12 stabilizes the full conductance state (Brillantes et al. 
1994; Ahern et al. 1997), the closed state (Timerman et al. 1993; Gaburjakova et 
al. 2001), and coupled gating between neighboring RyR1 channels (Brillantes et 
al. 1994; Marx et al. 1998), thus preventing spontaneous channel openings, and 
subconductance states. In addition, FKBP12 is proposed to enhance the gain of 
EC coupling in skeletal muscle (Lamb et al. 1996; Avila et al. 2003). But in 
cardicac myocytes, FKBP12 association to RyR2 could not reduce RyR2 activity 
(Ca2+ sparks) (Guo, et al, 2010). A similar role for FKBP12.6 as RyR2 channel-
stabilizing regulator has been supported by evidence from some groups (Kaftan 
et al. 1996; McCall et al. 1996; Xiao et al. 1997; Prestle et al. 2001; Xin et al. 
2002; George et al. 2003; Kohno et al. 2003; Yano et al. 2003) but are opposed 
by others (Timerman et al. 1996; Barg et al. 1997; Xiao et al. 2007; Jones et al. 
2008), so the function for FKBP12.6 as the RyR2 stablizer is still controversial 
(reviewed in “Main mechanisms for enhanced SR Ca2+ leak”). 
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Fluorescence resonance energy transfer (FRET) 
FRET is a phenomenon in which one excited chromophore (donor) can 
transfer its excitation energy to a nearby neighbor (acceptor). The energy 
transferred between the donor and acceptor is through nonradiative dipole–
dipole coupling (Volkhard 2007), which is a “radiationless” mechanism and 
termed "Förster resonance energy transfer". This name is from its discoverer, a 
German scientist Theodor Förster. In most cases, the FRET happened between 
fluorophores, where the energy transfering can be detected through fluorescence 
change. So it is also called "fluorescence resonance energy transfer". There are 
two requirements for fluorescence resonance energy transfer (FRET): one is the 
spectrum requirement, which is a significant overlap between the donor emission 
spectrum and acceptor absorption spectrum; the other one is proximity 
requirement, which means the distance between donor and acceptor must be 
minimal (usually less than 10nm).
FRET has a broad application for protein studies, especially worked as a 
sensitive molecular ruler for an accurate distance measurement between two 
labeled proteins and further defining the potential interaction between those two 
proteins (LeTilly and Royer, 1993). Another one of most important applications is 
to detect conformation changes within a protein complex, in which two domains 
are labeled with fluophores. The conformation change can be detected through 
FRET efficiency response which reflects the subtle change of two labeling 
fluophores’ orientation and distance (LeTilly and Royer, 1993). Additionally, 
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FRET is applied for many other studies like: protein sythesis and turnover, 
manipulation of protein activity, and monitoring enzyme activity, et al (Giepmans, 
Adams, Ellisman, and Tsien, 2006).
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CHAPTER III 
MATERIALS AND METHODS 
Heart Failure Model 
In Sprague-Dawley rats, heart failure was induced and developed by 
coronary ligation as Tanonaka approach (Tanonaka et al, 2001; Lin et al, 2007). 
The rat HF model, developed by Anne Knowlton’s lab (UC Davis), produces HF 
in 12 weeks after surgery. The animal protocol was approved by the University of 
California, Davis Animal Research Committee in accordance with the NIH Guide 
for the Care and Use of Laboratory Animals.
Cardiac myocyte isolation 
Isolation of ventricular myocytes was carried out as previous description 
(Li et al, 2002). RyR2+/ADA KI mice were provided by Dr G. Meissner (University 
of North Carolina). All procedures were performed according to the Guiding 
Principles in the Care and Use of the Animals approved by the Council of 
American Physiological Society. Hearts were excised from WT or RyR2+/ADA KI 
mice, rats (normal and HF). After the animal was anesthetized by 3-5% 
isoflurane for 1 min, hearts were excised out and hung on to a Langendorff 
perfusion apparatus (37 °C) via aortic cannulation and secured with a stainless 
steel alligator clip and tied with silk suture to the cannula. Hearts were perfused 
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at constant pressure with 0 Ca2+ NT through the coronary circulation for 
approximately 5 minutes. This assured that all blood was washed off from the 
coronary system. The perfusion solution was then switched to 0 Ca2+ NT solution 
containing 0.8 mg/ml collagenase (type B, Boehringer Mannheim) for 7-12 min, 
until the heart became flaccid. Hearts were then removed from the perfusion 
system and the atria were discarded. The ventricular tissue was chopped into 
small pieces and incubated for 10 min at 37?C in a shaking water bath in the 
presence of both collagenase and protease. Myocytes were subjected a 
dissociation by gentle agitation and filtered through two layers of gauze.  
Extracellular [Ca2+] was progressively raised to 1 mM in three successive 
washes, each 5 minutes. Myocytes were placed finally in NT solution (in mM): 
NaCl 140, KCl 4, MgCl2 1, CaCl2 1, glucose 10, HEPES 5, pH 7.4. All 
experiments were performed at room temperature (23 °C). 
Cell permeabilization 
Cell permeabilization provides a useful tool to control the intracellular 
environment and to introduce exogenous agents into cells while keeping relative 
intact cellular surroundings (Lukyanenko and Gyorke, 1999). Saponin 
permeabilization has been used in intracellular Ca2+ signal recording, such as 
Ca2+ spark/wave measurements through confocal microscopy.  In this project, 
through cell permeabilization, I can keep the [Ca2+]i  tightly controlled and prevent 
the complication from the L-type Ca2+ channels which localize on the 
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sarcolemmal membrane. The potential disadvantage of this method is that some 
cellular contents can be lost, which can be partially compensated by experiment 
design.
All myocytes originally suspended in NT solution were transfered to 
relaxation solution, and then were permeabilized by saponin (50ug/ml). For 
fluorescent protein required experiments, myocytes were permeabilized for 3 
minutes. For only fluorescent dye required experiments, myocytes were 
permeabilized for 20-30 seconds. Relaxation and permeabilization solution 
contain (mM): EGTA 0.1, HEPES 10, Kaspartate120, MgCl2 1, ATP 5, reduced 
glutathione 10, phosphocreatine di-Tris 5 and saponin 50 ug/ml (only in 
permeabilizing solution), pH 7.4. After permeabilization, myocytes were 
superperfused with internal solution (mmol/L): EGTA 0.5, HEPES 10, K-aspartate 
120, ATP 5; free MgCl2 1, reduced glutathione 10, [Ca2+] 50 nmol/L (calculated 
using MaxChelator), creatine phosphokinase 5 U/ml, phosphocreatine 10, 
dextran (MW: 40,000) 4%, pH 7.2. 
Fluoresent labeling of single-cysteine mutants of FKBP12.6 and CaM 
The fluorescent FKBP12.6 and CaM were provided by our collaborators: 
Dr Cornea and Dr Fruen (University of Minnesota). The cDNA of the human 
FKBP12.6 and CaM were subcloned into the NdeI/NheI site of the pRSET 
expression vector (Invitrogen). This hFKBP12.6/CaM clone was used as a site-
directed mutagenesis starting point to create null-Cys FKBP12.6 (C22A/C76I-
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FKBP12.6). Site-directed mutagenesis was carried out on these clones using 
quik change site-directed mutagenesis kits (Stratagene). Expression was carried 
out in the E. coli BL21 (DE3) pLysS cells, transformed with the mutagenized 
hFKBP-pRSET vectors.
Recombinant FKBP/CaM variants were purified by a procedure adapted 
from previous reports (Guo et al, 2010). Briefly, the cell lysate was subjected to 
40-60 % ammonium sulfate fractionation.  The 40-60% pellet was resolubilized in 
10-15 ml of 10 mM HEPES (pH 8.0), 1 mM DTT, 0.1 mM PMSF (Buffer A), 
dialyzed against 4 L of Buffer A, then subjected to isocratic anion exchange 
chromatography on DEAE Sephacel (35 ml gel, 3 cm diameter) pre-equilibrated 
in Buffer A. This column was developed with Buffer A at 0.5 ml/min and 
FKBP/CaM elutes in the first peak, which was then concentrated to 30 mg/ml, 
and NaCl was adjusted to 150 mM.  A 1 ml volume of this concentrate was then 
applied to a Sephacryl-200 HR (70 x 1.5 cm) pre-equilibrated with Buffer A 
supplemented with 150 mM NaCl (Buffer B) at a rate of 0.2 ml/min.  Fractions 
(1ml) were collected and analyzed by electrophoresis. The fractions containing 
>95% pure FKBP/CaM were pooled, and the purity of FKBP/CaM in this sample 
was further confirmed by SDS-PAGE. The typical yield was ~30 mg of pure 
proteins per liter of cell culture. The concentration of purified WT protein used as 
standard was determined by using their calculated extinction coefficients. 
The FKBP/CaM mutant was labeled at its single cysteine using the 
maleimide derivatives of Alexa Fluor 488 or Alexa Fluor 568. The FKBP/CaM 
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sample was treated with TCEP (1mM) for 1 hr in buffer containing 20 mM MOPS, 
150 mM NaCl, pH 7.5. The fluorophore was applied then from a DMF stock to a 
final concentration of 1.6 mM, DMF was adjusted to 20% by volume, and the 
reaction was allowed to proceed for 4 hrs at room temperature, with tumbling, 
protected from light.  Unreacted dye was removed by chromatography on DEAE 
Sephacel and the sample was dialyzed and concentrated using Amicon device 
(Millipore, Billerica, MA) into 20 mM MOPS, 30 mM NaCl, pH 7.0 at a protein 
concentration of 60-100 µM. 
Fluorescence Recovery after Photobleaching (FRAP) 
FRAP is a method that can be used to define protein binding kinetics 
through optical techniques. First, a protein binding region was photobleached by 
strong laser illumination, and then fluorescence recovery of this region is 
recorded. The fluorescence recovery in photobleached region is plotted vs time 
to yield a curve that reflects the kinetic coefficients for the protein's reversible 
binding. Diffusion and binding/unbinding are needed to be considered for the 
fluorescence recovery. If the diffusion is very fast and can be ignored in the 
whole process, the analysis is very simple since the fluorescence recovery is 
determined by the rate at which bleached bound proteins dissociate from their 
binding sites and are replaced by free fluorescent protein in the bath. Note that 
the recovery depends on dissociation rate (koff) only, not the association rate 
52
(kon). Some assumptions are necessary for the data interpretation (Bulinski, 
2001):
1. The concentration of bound protein region (like Z-line) is much higher than 
free protein concentration in the bath, so that the fluorescent contribution of 
the free protein can be neglected. 
2. There is no significant movement for bound proteins during recovery. 
3. Compared with binding/unbinding, the free diffusion is much faster. So that 
the contribution of fluorescence recovery by diffusion can be ignored, and 
recovery rate reflects the process in which the fluorescent free protein binds 
and replaces the bound photobleached protein and so recovers the 
fluorescence.  
After three assumptions are satisfied, we can fit the recovery curve with single 
exponential function and find the on- and off-rate constants for protein binding. In 
my experiments, all these assumption are statisfied.
Permeabilized myocytes were incubated with FRET pair: 100nM 
fluorescent FKBP12.6 (F-FKBP12.6, donor) and a range of fluorescent CaM [F-
CaM (acceptor)]s. F-CaM bound on RyR2 was detected through FRET by 
sensitized emission. After steady state was reached, F-CaM was photobleached 
at Z-lines though 543nM excitation with high laser power (90%) for 50s, resulting 
in >95% exposed F-CaM fluophore destruction. Thereafter the patterned striation 
recovery of photobleached region was recorded in the FRET acceptor channel 
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(488nM excitation, >600nM recording). This reflects recovery of RyR2 bound 
CaM through reversible binding, which can be modeled as a first order reaction. 
The observed recovery rate constant kFRAP was fitted by a single-exponential 
function. The observed recovery rate constant, kFRAP, is an integrated 
measurement depending on both kon and koff, which can be described by the 
equation:
kFRAP= kon[F-CaM] + koff.
Since kFRAP is F-CaM concentration dependent, measured kFRAP at various [F-
CaM] allows measurement of kon (slope) and koff (intercept) in a linear fitting (Guo 
et al, 2010). Three conditions are important for accurate measurement. 1) There 
should be no pre-bound endogenous CaM, which was predepleted by suramin. 
2) The initial F-CaM application should be around the ~Kd range. 3) The diffusion 
of F-CaM should be much faster than binding/unbinding process, such that it is 
not the rate-limiting step.
FRET between F-CaMs and F-FKBP in permeabilized myocytes 
For the FRET between FKBP12.6 and CaM, we used fluorescent 
FKBP12.6, labeled at position 14 with green-fluorescent Alexa 488 (AF488-14-
FKBP12.6), and F-CaM labeled with red-fluorescent Alexa 568 attached at the 
position 34 (AF568-34-CaM) (Cornea et al, 2009; Guo et al, 2010 & 2011). After 
permeabilization, myocytes were placed in internal solution. Fluorescent 
FKBP12.6 and CaM were added to the bath solution. F-FKBP12.6 (donor) was 
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excited at 488 nm, and emission was recorded through a 500-530nm band pass 
filter (donor channel). F-CaM (acceptor for FRET) fluorescence emission was 
recorded by sensitized emission through a >600nm filter (acceptor channel). We 
utilized two experimental approaches, (1) comparing the donor fluorescence 
intensities before and after equilibrating with the acceptor (donor quenching) and 
(2) monitoring the increase in donor fluorescence after acceptor photobleaching 
(acceptor photobleaching), to detect and measure FRET signals in the 
permeabilized cardiomyocytes.  
For the donor quenching method, FRET is indicated by a decrease in the 
donor fluorescence at wavelengths 500-530 nm (AF488-FKBP12.6), after 
acceptor is added and reaches equilibrium. Both donor and acceptor saturate 
RyR binding sites. The FRET efficiency is calculated based on the equation:  
E = 1 - FDA/FD,
FD is for the fluorescence intensities of the donor-only state, FDA stands for the 
fluorescence recorded through donor channel after adding the acceptor. 
         For Acceptor photobleaching, permeabilized myocytes were first incubated 
with AF488-FKBP12.6 and AF568-34-CaM to reach equilibrium. The acceptor 
photobleaching was achieved by repeated scans with maximum laser power at 
543 nm for 60 sec to completely photobleach the acceptor (AF568-34-CaM). 
There is an increase in donor fluorescence signal when FRET is disrupted by 
photobleaching of acceptor fluorophore. The FRET efficiency was calculated 
according to the equation:
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E = [(Idonor-post – Idonor-pre)/Idonor-post] x 100%,
where Idonor-post and Idonor-pre are donor fluorescence intensity after and before 
photobleaching of acceptor fluorescence.
Donor-acceptor distances, R, were calculated from the equation:  
R = R0 (E-1-1)1/6,
where the Förster distance, R0 is defined as the distance at which FRET=0.5. 
Here R0 for AF-488 and AF568 is 62Å (Invitrogen.com). 
Two control experiments are needed for FRET measurement to detect 
potential bleeding through or cross talk between donor and acceptor. 1), with 
donor alone (AF488-FKBP12.6), acceptor channel whether can detect any signal 
due to the excitation of donor. 2), with acceptor alone (AF568-34-CaM), donor 
channel whether can detect any signal when acceptors were directly excited 
through 543nM laser illumination.
Wash-in/off in myocytes 
Fluorescence changes, after a rapid wash-in and wash-off of fluorescent 
protein (F-CaM or F-DPc10), can be used to estimate protein binding kinetics in 
permeabilized myocytes. After permeabilization, pretreatment was applied to 
predeplete possible endogenous bound CaM and made the binding site available 
for fluorescent protein. Then I washed in fluorescent protein and recorded the 
fluorescence increase in myocytes over time. After the fluorescence reached 
steady state, I washed fluorescent protein off by internal solution and recorded 
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fluorescence decrease, which was fitted with a single-exponential function. For 
wash-off, I can establish koff by fitting the equation: specific-binding = A ? exp (-
koff ? t), here A stands for the specific binding (fluorescent value) at equilibrium. 
For wash-in experiment, I can fit the association rate constant (kob) by the 
equation: specific binding = A ? (1 - exp (-kob ? t)), from which kon can be 
calculated through kob = koff + kon[F-CaM].
Ca2+ signal measurement by fluo-4 with confocal microscopy 
1. Ca2+ signal recording in intact myocytes 
Ca2+ transients were recorded using 5 µM fluo-4-AM dye loading, a single-
wavelength Ca2+ indicator, and the laser scanning confocal microscope (BioRad, 
Carl Zeiss).  The confocal microscope is equipped with a 40x oil immersion 
objective lens (n.a. = 1.3).  Fluo-4 was excited with the 488 nm line of an argon 
laser.  Emitted fluorescence was collected through a 500-530 nM band pass 
emission filter.  Fluo-4 images were recorded in the line-scan mode with 512 
pixels per line at 166 Hz. Ca2+ transients were obtained by field stimulation at 1 
Hz in normal Tyrode’s solution; the amplitude of Ca2+ transient was presented by 
F/F0; the time constant was fitted by one exponential; SR Ca2+ load was 
assessed by the rapid application of 15 mM caffeine in the normal tyrode (NT). 
2. Ca2+ spark measurement and analysis 
Ca2+ sparks were recorded in saponin-permeabilized ventricular 
cardiomyocytes, which were superfused by internal solution with free 50nM / 
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100nM [Ca2+]. Sparks were counted and characterized by an algorithm in 
Interactive Data Language (IDL 5.3 computer software) (Cheng et al., 1999).  
The program detects Ca2+ sparks as areas of increased fluorescence compared 
to the standard deviation (SD) of the background of the fluorescence image.  We 
used the Ca2+ spark measurement threshold 3.8 ? s.d., with human verification of 
Ca2+ spark detection. Ca2+ spark amplitudes were normalized (F/F0) to 
fluorescence baseline (F0). Duration of Ca2+ sparks was taken from the dwell 
time at > 50% of the peak level (full-duration-half-maximum, FDHM).  Width of 
the Ca2+ sparks was indicated by the spatial size at > 50% of the peak level (full-
width-half-maximum, FWHM).  Ca2+ spark frequency (CaSpF) was normalized to 
time and spatial size of the volume elements (or voxels) of the cell from which 
Ca2+ sparks are measured. It is based on point spread function of the confocal 
microscope. Under our conditions (zoom = 3.0), the width and length of one voxel 
is 0.2 ?m & 0.2 ?m, and the depth (assumed) is 1 ?m, so the voxel is 0.04 ?m3.
The fluorescence images were recorded in longitudinal line-scan mode (512
pixels per line), such that the volume of one scan line corresponds to 0.04 ?m3
times the number of pixels that are within the cell length. 
Statistics
Data are expressed as mean +/- SEM. Significance is evaluated by using 
paired or unpaired Student’s t test. One way analysis of variance (ANOVA) was 
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used for multiple comparison. P < 0.05 was considered to be statistically 
significant. 
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 CHAPTER IV 
HYPOTHESES AND AIMS 
Cardiac ryanodine receptors (RyR2), intracellular Ca2+ release channels, 
play a central role in excitation-contraction coupling (ECC). A dysfunctional 
RyR2, exhibiting enhanced diastolic Ca2+ leak, has been implicated in 
arrhythmogenesis and heart failure (HF). Excessive diastolic sarcoplasmic 
reticulum (SR) Ca2+ leak can reduce SR Ca2+ load and generate cardiac 
arrhythmia. Therefore, the RyR2 leakiness regulation (without affecting normal 
ECC) is a potentially valuable modality for the treatment of cardiac arrhythmias 
and HF. As an important regulator, calmodulin (CaM) binds and stabilizes RyR2. 
Single channel studies suggest that CaM inhibits the RyR2 during diastole and 
may regulate the shut off of Ca2+ induced Ca2+ release (CICR) during systole. 
And defective CaM-RyR2 interaction is broadly implicated in HF and CPVT 
models. All these indicate CaM’s essentially patho-physiological meaning for 
RyR2 regulation.  However, direct measurements of RyR2-CaM interaction in 
myocytes are lacking despite its potential clinical importance. My goal here is to 
define the physical RyR2-CaM interaction and its functional consequences in 
situ. The central hypothesis is that the stoichiometry and degree of RyR-CaM 
binding are key determinants in local SR Ca2+ release. Using fluorescent 
FKBP12.6 and CaM as well as transgenic mice with defective RyR2-CaM 
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interaction, I combine FRET and FRAP, Ca2+ sparks measurement, and domain 
unzipping peptide (DPc10) to assess both the RyR2-CaM physical interaction 
and its functional importance in the native myocyte environment. 
Aim 1. Measure the physical in situ binding properties of RyR2-CaM.
CaM has numerous downstream target proteins beside the RyR2, such as 
the L-type Ca2+ channel (LTCC), calcineurin (CaN), and Ca2+-CaM dependent 
protein kinase II (CaMKII). To minimize interfering nonspecific signals from other 
targets, we can use FRET detection to define the RyR2 bound CaM. Studies 
indicate that FKBP12.6 and CaM specifically bind to RyR2 in a physically close 
enough proximity to produce measurable FRET which is not expected at other 
sites. I apply F-FKBP12.6 and F-CaM in saponin-permeabilized cardiac 
myocytes and provide original direct measurements of: 1) FRET between CaM 
and FKBP12.6 on RyR2 in permeabilized myocytes; 2) RyR2-CaM binding 
properties (steady-state affinity, on-& off-rates) from three independent methods; 
3) the percentage of Z-line bound CaM is on RyR2 through using knock-in mice, 
where a triple-mutation (RyR2ADA) prevents CaM binding to RyR2. The 
differences of binding stoichiometry and degree of RyR2-CaM interaction 
between WT and knock-in mice would be correlated with functional attributes of 
SR Ca2+ release in specific aim 2. 
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Aim 2. Define  the physiological consequences of RyR2-CaM binding in 
cardiac myocytes.  
In recent years, CaM has emerged as a critical regulator of SR Ca2+
release. Specifically, CaM helps maintain the RyR2 in a closed state during 
diastole and facilitates termination of Ca2+ release by decreasing the probability 
of channel reopening and prolonging the closed times. In non-ischemic canine 
and rabbit HF models, there is a decreased CaM binding to RyR2 without 
changes in total CaM. Based on previously published results and our preliminary 
data, I hypothesize that disrupting the RyR2-CaM interaction will lead to aberrant 
activation of RyR2 during diastole and systole that could be arrhythmogenic and 
contributing to HF. This could be manifested as aberrant diastolic and systolic 
Ca2+ release. Using knock-in mice having defective RyR2-CaM interaction 
(where interaction with other CaM downstream targets is not affected), I will 
measure the diastolic Ca2+ leak in permeabilized myocytes where [Ca2+]i is tightly 
controlled, and systolic Ca2+ transient and fractional release in intact myocytes. 
The outcome will provide critical new information concerning how RyR2-CaM 
interaction influences SR Ca2+ release in myocytes.
Aim 3. Define RyR2-CaM binding affinity in heart failure myocytes.  
The affinity of RyR2 binding to both CaM and FKBP12.6 are reported to 
be decreased in HF animal model (Ai et al, 2005, Ono et al, 2010). However, 
most measurements have been done by using either SR vesicles or cell lysates. 
62
Here for the first time, we use coronary ligation induced rat HF model to define 
RyR2 binding affinity to CaM and FKBP12.6 in situ.
Aim 4. Define CaM as a critical RyR2 stabilizer through RyR2 unzipping 
peptide (DPc10).
One hypothesis for elevated Ca2+ leak through cardiac ryanodine 
receptors (RyR2) in heart failure (HF) is interdomain “unzipping” that can 
enhance aberrant channel activation.  A peptide (DPc10) corresponding to RyR2 
central domain 2460-2495 mimics this arrhythmogenic RyR2 leakiness by 
unzipping N- and central-domains. CaM binds to RyR2 and stabilizes the closed 
channel. Little is known about DPc10 binding to the RyR2 and how that may 
interact with binding (and effects) of CaM with RyR2. There are 3 small aims to 
reveal DPc10 binding kinetics and the relation between CaM and domain 
unzipping: 1). DPc10 could bind to RyR2 in a conformation-dependent manner; 
2). CaM can prevent RyR2 unzipping caused by DPc10 binding; 3). RyR2 
unzipping by DPc10 can decrease CaM binding affinity to RyR2.
All those aims can lead to a better understanding about RyR2-CaM 
interaction and functional effects on RyR-mediated Ca release in cardiac 
myocytes.
63
CHAPTER V 
Kinetics of Calmodulin Binding to Cardiac Ryanodine Receptors 
and Functional Consequences 
INTRODUCTION
Approximately 50% of heart failure patients die of ventricular arrhythmia 
and sudden cardiac death (Noseworthy & Christopher, 2008). Now it is well 
known that RyR2 mediated SR Ca2+ leak could activate inward current through 
Na/Ca exchanger and evoke delayed after depolarizations (Vermeulen et al, 
1994). In HF there is enhanced diastolic SR Ca2+ leak via RyR2 and other 
electrophysiological changes (e.g. up-regulation of NCX) that greatly enhance 
the propensity for DADs and triggered cardiac arrhythmias (Pogwizd and Bers, 
2002; Bers, Pogwizd and Klaus 2002), which is proved to be the leading reason 
for ventricular tachyarrhythmia and sudden cardiac death (Pogwizd & Bers, 2004; 
Shannon, Pogwizd and Bers, 2003). Because of RyR2 has emerged as a 
potential therapeutic target for treating HF and arrhythmia. Therefore, stabilizing 
RyR2 and preventing abnormal Ca2+ leak (without affecting normal excitation 
contraction coupling) is a potentially valuable modality for the treatment of 
cardiac arrhythmias and HF. 
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Calmodulin is a very important RyR2 regulator, but also has many cellular 
binding partners involved in different cellular processes. With 148 highly 
conserved residues, CaM has two pairs of globular Ca2+ binding E-F hand 
domains connected by a flexible tether helix (Jurado, Chockalingam and Jarret, 
1991). At high [Ca2+], Ca2+ binds cooperatively to CaM and result in 
conformational change that translate intracellur [Ca2+] signals to diverse targets, 
including: myosin light chain kinase (MLCK), protein phosphatase calcineurin 
(CaN), nitric-oxide synthase (NOS), phosphodiesterase (PDE), adenylyl cyclase 
(AC), Ca2+/CaM-dependent kinase (CaMK), Ca2+-activated potassium channels, 
L-type Ca2+ channels (LTCC) and RyRs (Means et al, 1991; Vogel 1994; James 
et al, 1995; Maier and Bers, 2002). 
CaM binds to RyR2 stoichiometrically (four CaMs per tetrameric RyR2), 
and works as a critical regulator for SR Ca2+ release. Cryo-EM based 3D RyR 
reconstruction showed that Ca2+-free CaM (apoCaM) binds to a cleft in the 
cytosolic domain 3 (AA 3583-3603) (Yamaguchi et al, 2003), with a distance of 
60-70Å to FKBP12.6 bound to the same RyR2 face (Moore et al, 1999; 
Wagenknecht et al, 1994), and FRET can occur between these two partners 
(Cornea et al, 2009; Guo et al, 2011). FKBP12.6 was reported to bind RyR2 
tightly as an important regulator in RyR2 gating but some aspects are still 
controversial (Brillantes et al, 1994; Marx et al, 1998; Barg et al, 1997; Guo et al, 
2010). It was reported that CaM could stabilize the RyR2 in closed state during 
diastole and could facilitate the termination of Ca2+ release by decreasing the 
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probability of channel reopening and prolonging the closed time (Xu et al, 2004). 
Additionally, defective RyR2-CaM interaction has potentially broad implication in 
cardiac pathology. Mutations of critical residues in the highly conserved CaM 
binding region can severely abolish CaM binding to RyR2 and cause severe 
hypertrophic cardiomyopathy and early death in animal models (Yamaguchi et al, 
2007). In non-ischemic HF animal models, CaM binding to RyR2 was decreased 
(Ai et al, 2005; Ono et al, 2010). A recent study indicates that defective CaM 
binding to RyR2 is also involved in CPVT-associated RyR2 dysfunction (Xu et al, 
2010). All these studies suggest that CaM-RyR2 interaction is a critical molecular 
substrate for arrhythmias and HF pathogenesis.  
However, due to its multiple binding targets, CaM-RyR2 binding affinity is 
measured in isolated systems, SR vesicles, lipid bilayers or cell lysates, rather 
than in native cells. Here by using FRET, we can identify RyR-bound CaM vs its 
numerous other target proteins, and for the first time we characterize CaM-RyR2 
interaction properties both for the normal and HF cardiomyocytes in the native 
cellular environments. The knock-in mice (RyR2+/ADA) (Yamaguchi et al, 2007), 
with genetically disrupted CaM-RyR2 association while the interaction with other 
CaM targets are not affected, are used to estimate the percentage of Z-line 
bound CaM that is on RyR2, and further define pathophysiological consequences 
of CaM for RyR2 regulation in cardiomyocytes. 
MATERIALS AND METHODS 
Pretreatment with suramin to predeplete bound endogenous CaM.  
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In resting cardiomyocytes, endogenous CaM is already prebound to most 
binding sites. We used suramin to predeplete endogenous bound CaM and make 
binding sites accessible for F-CaM, allowing accurate measurement of associ-
ation kinetics. After myocytes permeabilization, suramin (5μM) was applied for 
5min, and then followed the wash-off with internal solution for 20 min.
FRET measurement for F-FKBP12.6 and F-CaM on RyR2 in permeabilized 
myocytes.  
See details in chapter III 
FRET + steady-state concentration -dependent CaM binding in myocytes.  
Myocytes were first superfused with relaxing solution, and then 
permeabilized with saponin. Once permeabilized, myocytes were incubated with 
5 μM suramin solution for 5min to predeplete endogenous bound CaM and then 
washed for 20min by internal solution. Then 100nM AF488-FKBP12.6 was 
washed in to saturate FKBP binding site on RyR2. After that AF543-CaM in 
different concentrations was washed in, with binding allowed to reach steady 
state. Excitation wavelengths is 488 nM for FRET and 543 nM for direct Z-line 
CaM measurement. For FRET, emission is recorded at 500-530nM for donor 
channel and >600nM for acceptor channel. Thus we have two sets of 
measurements, one for CaM binding at the Z-line (direct fluorescence) and one 
that is specific for RyR2 bound CaM (FRET). 
In situ FRET + FRAP, to measure kon & koff for CaM-RyR2 interaction. 
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Permeabilized myocytes are incubated with 100nM F-FKBP12.6 and a 
range of [F-CaM]s, each until steady state is reached. Z-line bound F-CaM will be 
photobleached by 543nM excitation with high laser power (90%) for 50s, 
resulting in >95% fluophore destruction. Thereafter the recovery of striation 
pattern in photobleached region is recorded through the FRET acceptor channel 
(488nM excitation, >600nM recording). 
FRET + wash-in/off for the measurement of kon and koff for CaM-RyR2 
interaction.  
FRET fluorescence changes were monitored in rapid wash-in and wash-
off of F-CaM in permeabilized myocytes. After pretreatment with suramin, the 
permeabilized myocytes were first saturated with F-FKBP12.6 (100 nM). This 
gave a strong striation pattern in the donor channel. While keeping RyR2 
saturated with F-FKBP12.6, F-CaM was washed in and the fluorescence 
changes over time in both donor and acceptor channel were recorded. After the 
fluorescence reaching steady state, F-CaM was washed out with keeping RyR2 
saturated with F-FKBP12.6 (with excess non-fluorescent CaM to prevent 
rebinding of F-CaM), and the fluorescence got recorded in acceptor channel.  
Confocal Ca2+ imaging 
Ca2+ sparks were measured as a readout for diastolic RyR2 activity in 
saponin-permeabilized (20-30 seconds) ventricular cardiomyocytes, which were 
superfused by internal solution with free 50nM/100nM Ca2+. For details see 
section III.
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For systolic RyR2 function test, intact ventricular myocytes were loaded 
with Fluo-4 AM (5 ?M, Molecular Probes) and Ca2+ transients were recorded as 
previously described (Van Oort et al, 2010). Ca2+ transients were obtained by 
field stimulation at 1 Hz in normal Tyrode’s solution. SR Ca2+ load was evaluated 
by Ca2+ transient upon rapid caffeine application (10 mM). Experiments were 
performed on a confocal microscope (BioRad, Radiance 2100, 40x objective) in 
line scan mode with argon laser (?ex 488 nm, ?em >505 nm). Image analysis 
was done with ImageJ, Ca2+ spark master and custom made software 
implemented in LabVIEW® (National instrumental Ive). 
Heart Failure Model 
In Sprague-Dawley rats, heart failure was induced and developed by 
coronary ligation describled as the approach of Tanonaka (Tanonaka et al, 2001; 
Lin et al, 2007). The rat HF model, developed by Ann Knowlton’s lab (UCD), 
produces HF in 12 weeks after surgery. 
RESULTS
Predepletion of endogenous CaM by suramin 
RyR2s are concentrated along the Z-line, and previous studies showed 
that CaM is highly concentrated within the same Z-line region and >90% apoCaM 
binding sites are occupied by endogenous CaM (Wu et al, 2007). Fig 4A(i) shows 
the striation image of fluorescent CaM (F-CaM) concentrated on Z-line, after 
60nM [F-CaM] was washed in. Suramin (5μM) can totally abolish the striations 
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within 1 min (Fig 4A (ii)); after the wash-off of suramin, F-CaM can rebind at the 
Z-line with the same striation pattern (Fig. 4A (iii)).  Before suramin treatment, F-
CaM washed in and yield a moderately slow increase of F-CaM fluorescence at 
the Z-line (? = 11.5 min, Fig. 4B). This slow phase represents F-CaM replacing 
endogenous bound CaM (Wu et al, 2007). After suramin depleted F-CaM binding 
and was washed off for 20 min (hydrophilicity allows rapid reversibility), F-CaM 
rebinds much faster at Z-line (Fig. 4C). Now F-CaM striations appeared with ?fast
= 2 min, which represents the time constant for F-CaM binding to unoccupied 
binding sites at Z-line. Since Bmax before and after suramin treatment are the 
same, we think suramin may completely deplete endogenous CaM bound at Z-
line which are then totally washed off. 
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Fig 4: Suramin can predeplete endogenous CaM. A, confocal 
images of saponin-permeabilized myocytes incubated with 60nM F-CaM in 
different conditions. (i), after 40min incubation, fluorescent striations reached 
Bmax. (ii), 10uM suramin can totally abolish fluorescent striations within 1 min. 
(iii), after suramin treatment and rewash-in F-CaM, fluorescent striation 
reached Bmax much faster. B, time course for 60nM F-CaM wash-in, 
immediately after permeabilization. C, time course for 60nM F-CaM rewash-
in, after suramin treatment.   
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FRET between FKBP12.6 and CaM on the RyR 
Both CaM and FKBP12.6 bind RyR1 at a very close proximity and get 
FRET interaction (Cornea et al, 2009). In cardiac myocytes CaM and FKBP12.6 
are concentrated at the Z-line (Guo et al, 2010; Xu et al, 2007). Here, using 
acceptor photobleach, we investigate the efficiency of FRET pair (F-FKBP and F-
CaM) which reflects the distance between these two proteins on RyR2 in cardiac 
myocytes. After F-FKBP12.6 and F-CaM are preequilibrated, we observed 
striation both at donor channel (green, Em = 500-530 nM) and acceptor channel 
(red, Em > 600 nM). Acceptor (F-CaM) was selectively photobleached by 
powerful 543nM excitation in the central region, while the donor fluorescence got 
enhanced only in this region (Fig 5A). The average FRET efficiency is 0.35 ± 
0.04 (n=8) reflecting a distance of 69 ± 0.7 Å (Fig 5B) between this FRET pair, 
which matches well with the result on RyR1 (Cornea et al, 2009). As a valuable 
control, repeating the photobleaching with only AF488-FKBP12.6 present had no 
effect on donor emission (Fig. 5C).  Based on a RyR1 EM-model, the distance 
between FKBP and ApoCaMs on the same side of RyR is 50-60 Å (Samso et al, 
2002), which is well within the FRET range (10-100 Å). The distance between 
FKBP12.6 and CaMs on other RyR faces could be: R2=122 Å, R3=232 Å and 
R4=207 Å (Fig 5D), which are all out range of FRET with respect to AF488 and 
AF568 (R0 = 62 Å). Therefore, we think 69 ± 0.7 Å is the distance for the same 
side FKBP12.6 and CaM, and there is no possibility of FRET interference from 
the other side of RyR2.   
72
Fig 5: FRET between F-FKBP12.6 (donor) and F-CaM (acceptor) 
in permeabilized rat myocytes. A, permeabilized myocytes were 
incubated with 100nM F-FKBP12.6 and 1uM F-CaM to reach steady-state. 
After acceptor photobleaching, there is a fluorescence enhancement in 
donor channel. B, the average FRET efficiency and reflected distance for F-
FKBP12.6 and F-CaM on RyR2. C, acceptor photobleaching had no effect 
on donor emission. D, based on RyR1 EM-model, the distance between F-
FKBP and F-CaM on the same face of RyR (R1) is 50-60Å (Samso et al, 
2002); the distances to other side potential FRET partner (R2, R3, R4) are 
out of FRET range.
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Measurement of binding affinity (Kd) of CaM-RyR2 
The strong FRET interaction between F-FKBP12.6 and F-CaM provides 
us with an effective approach to distinguish CaM bound to RyR2 vs other CaM 
binding partners (Guo et al, 2011). After suramin pretreatment, 100nM AF488-
FKBP12.6 (donor) first was washed in to saturate FKBP binding site on RyR2 
(Guo et al, 2011), then AF543-CaM (acceptor) at different concentrations was 
washed in, with binding allowed to reach steady state. The RyR2 bound CaM can 
be detected through FRET by sensitized emission, where excitation wavelengths 
is 488 nM for FRET measurement and emission is recorded at 500-530nm for 
donor and >600nm for acceptor. Fig. 6A shows the fluorescent cross striation 
pattern at 2 different [F-CaM]s in both donor channel (green, Em= 500-530nm) 
and acceptor channel (red, Em>600nm). With high [F-CaM] there is a reduced 
donor and an increased acceptor (FRET) signal. In the acceptor channel, the 
heights of the FRET signal peaks (difference between Z-line and M-line) 
represent the amount of CaM specifically bound to RyR2, which are well fitted 
with single specific binding curve with Kd=18.2 ± 2 nM (Fig 6B). To test whether 
these FRET measurements reflect 1:1 transfer betweent F-CaM and F-
FKBP12.6, we plotted the donor fluorescence change upon acceptor binding 
increase. A linear relationship reveals a 1:1 ratio for donor and acceptor (Fig 6C). 
Thus the source of FRET appears to be exclusively between FKBP12.6 and CaM 
bound to the same face of the RyR2 (e.g. not on anther nearby protein).
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Fig 6: Kd for RyR2 bound CaM. A, the FRET images for 2 
different acceptor [F-CaM]s, while keeping the donor saturated. There is a 
decreased donor signal but increased signal acceptor for high [F-CaM] 
incubation. B, signal in acceptor channel was fitted with single saturable 
binding revealed the binding affinity for CaM-RyR2 (n=11-13). C, the 
donor fluorescence decreased upon the acceptor binding, a linear 
relationship revealed a 1:1 donor and acceptor ratio (n=11-13).
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Since in FRET the fluorescent energy transferred between donor and 
acceptor, and the ratio of donor and acceptor is 1:1, then we can fit the Kd value
from both donor and acceptor signals. We plotted the mean fluorescence value 
of donor or acceptor fluorescence versus CaM concentration. The acceptor 
fluorescence was fitted by equation:  
F(acceptor) = Bmax x [CaM] / (Kd + [CaM]), Kd = 18.2 nM (Fig 7) 
And donor fluorescence was fitted by equation: 
F(donor) = C – Bmin x [CaM] / (Kd + [CaM]), C stands for the donor max 
fluorescence without the acceptor, and Kd = 19.4 nM (Fig 7) 
 We can see that both Kd values fitted from the donor and acceptor signals are 
very similar, testing that the Kd value is correctly estimated.  
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Fig 7: Kd fitting from both donor and acceptor signals. C is the max 
donor fluorescent value without the acceptor.
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Furthermore, by using direct 543nm F-CaM excitation (not FRET), we 
measured the Kd for Z-line total CaM (CaM bound to RyR2 plus other sites along 
the Z-line). Fig 8A shows the Z-line striated pattern by direct excitation at 
different [F-CaM]s. Similarly, the plot of peak height reveals a single saturable 
binding component for F-CaM at the Z line with the Kd of 17.2 ? 1.8 nM (Fig. 8C). 
The Kd values for RyR2-CaM and Z-line CaM are very close. One possible 
explanation is that RyR2 is the quantitatively dominant CaM binding site in the Z-
line. The other is that several CaM binding sites have almost the same apparent 
affinity. Through linear bath [F-CaM] calibration (Fig 8B), we can infer the 
concentration of Z-line bound F-CaM in permeabilized myocytes. The CaM (Bmax)
reflects the total amount of binding of CaM on Z-lines,(1.2 μM). These CaM 
binding values are similar to our prior work (Song et al, 2009) and consistent with 
FKBP12.6 binding in rat myocytes (Guo et al, 2010. 
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Fig 8: Steady-state Kd and Bmax for Z-line total CaM. A,
confocal Z-line images for two different [F-CaM]. B, calibration upon bath 
fluorescence on different F-CaM concentration (n=11-13).  C, binding 
affinity fitting for CaM on Z-line, reflecting the Kd and total CaM (Bmax) on 
Z-line (n=11-13).
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Measurement of binding kinetics of CaM-RyR2 
 Measurement of kon and koff for CaM-RyR2 by FRET + wash-in/off in 
myocytes. After pretreatment with suramin, the permeabilized myocytes are 
saturated with F-FKBP12.6 (100 nM). Using FRET, we can characterize CaM-
RyR2 association (kon) and dissociation (koff) rate in wash-in/off experiment. Fig 
9A illustrates a representative time course of FRET intensity in the 20nM [F-CaM] 
continuous wash-in/off experiment. For wash-off, the fluorescent striation pattern 
gradually declined and followed the single exponential decay with a time constant 
of 4.5 min, which means koff = 0.22 ± 0.01 min-1 (n=5). For wash-in, the 
association rate is dependent on the on-, off-rate and [F-CaM] (kwashin = kon [CaM] 
+ koff). Since kwashin can be fitted, we can calculate kon =18.9 ± 1.6 x 106min-1M-1
(n=5). Based on kon and koff, Kd can be calculated (Kd = koff / kon = 12 ± 0.9 nM), 
and is consistent with the result from the steady-state binding experiment.
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Fig 9: CaM-RyR2 on- & off-rate measured by FRET + wash-
in/off (n=5). Representative time course of FRET CaM fluoresence 
intensity in 20nM [F-CaM] continuous wash-in/off.  
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Using FRET + in situ FRAP, to measure kon & koff for CaM binding to RyR2 
in myocytes. Permeabilized myocytes were first equilibrated with saturating F-
FKBP12.6 (100nM) and [F-CaM] in Kd range. After photobleaching the acceptor 
by 543nM excitation, there is a recovery of photobleached striation pattern. The 
recovery of FRET allows a measurement of RyR2-bound CaM recovey rate 
(kFRAP). This recovery reflects reversible CaM-RyR2 binding, in which the 
photobleached RyR-bound F-CaM was replaced by fresh F-CaM from the bath. 
Fig 10A shows the recovery of FRET in 20nM bath [F-CaM] at different times.  In 
Fig 10B, kFRAP was fitted by single-exponential function in two different bath [F-
CaM]s, on which the fluorescence recovery is dependent. According to the 
equation: kFRAP= kon[F-CaM] + koff, kon (slope) and koff (intercept) were fitted by 
linear regression (Fig 10C). Both kon = 14.5 ± 2.5 x106 min-1 M-1 and koff = 0.144 ± 
0.05 min-1 agree well with wash-in/off experiment, and calculated Kd = 10 ± 2 nM 
also matches results above.
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Fig 10: CaM-RyR2 on-& off-rates measured by FRAP. A,
recovery of photobleached striation image in 20nM [F-CaM] over different 
time. B, KFRAP was fitted with single-exponential funcition in two different 
bath F-CaM concentrations. C, kon (slope) and koff (intercept) are fitted 
through linear regression (n=8-10), and Kd is calculated.   
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Estimating the percentage of Z-line total CaM that is RyR2-bound  
Knock-in mice with genetically disrupted CaM-RyR2 interaction are used 
here (along with WT mice) to test the percentage of Z-line total CaM that is due 
to RyR2, vs other CaM binding targets, like LTCC. These knock-in mice express 
RyR2 with a triple-mutation (RyR2-W3587A/L3597D/F3603A), where the binding 
of CaM to RyR2 is dramatically impaired without interfering with other CaM 
signaling pathways (Yamaguchi et al, 2007). Notably, these mice, when 
homozygous, die very soon after birth; however the heterozygous mice survive 
long enough to be useful experimental animals (Yamaguchi et al, 2007). In 
steady state binding, we detect a decrease both for CaM binding on RyR2 by 
FRET, and Z-line total bound CaM by direct F-CaM exitation (Fig 11A, B).  For 
RyR2ADA/+, there is a 50% reduction in the FRET with unchanged binding affinity 
(Fig. 12A), which fits the expectation that in heterozygous mice 50% RyR2 
monomers have the triple-mutation. But for the Z-line total CaM, there is a 46% 
reduction (Fig. 12B), which is due to 50% decrease in CaM binding to RyR2. This 
means ~92% of Z-line localized CaM is on RyR2. In control experiments (Fig 13 
A & B), we tested that the total binding (Bmax) of FKBP12.6 to RyR2ADA/+ and WT 
myocytes is unchanged, indicating that the total number of RyR2 monomers is 
the same, which matches previous [3H] ryanodine binding experiments in these 
mice (Yamaguchi et al, 2007). 
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Fig 11: Confocal images for RyR2 bound FRET CaM and Z-line 
bound total CaM (RyR2ADA/+ vs WT). A, FRET images in saturating 
condition for WT and RyR2ADA/+, Bmax (FRET CaM) decreased for 
RyR2ADA/+ mutant. B, Z-line total bound F-CaM images for WT and 
RyR2ADA/+.
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Fig 12: Percentage of Z-line CaM that is bound to RyR2. A, for 
RyR2ADA/+ in steady state binding, Bmax (FRET CaM) decreased ~50% with 
a similar Kd compared with WT (n=12-20). B, for Z-line bound total CaM in 
RyR2ADA/+, Bmax decreased 46% (n=14-20), which is due to RyR2 bound 
CaM 50% reduction, so ~92% of Z-line bound CaM is on RyR2. 
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Fig 13: Total binding (Bmax) of FKBP12.6 for WT and RyR2ADA/+
mice. A, The confocal images of F-FKBP12.6 binding for WT and 
RyR2ADA/+. B, Bmax (100nM) is the same for RyR2ADA/+ and WT (n=20).
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Ca2+ sparks in permeabilized RyR2+/ADA KI mouse myocytes 
Saponin-permeabilized myocytes are powerful tools for the evaluation of 
diastolic SR Ca2+ leak. Through cell permeabilization, we can tightly controll the 
[Ca2+]i and prevent complications from L-type Ca2+ channels which also can 
trigger RyR2 mediated Ca2+ release. However, the potential disadvantage of this 
method is that some cellular contents (like endogenous proteins) can be lost due 
to wash-off. Since the endogenous CaM associated with RyR2 may be washed 
off within 5 min (Fig 9A), we modified the permeabilizing protocol for Ca2+ spark 
measurement to partially compensate this disadvantage. For the Ca2+ spark
measurement here, myocytes were exposed to 50μg/ml saponin for only 20-30 s’ 
instead of the 3 min used above for CaM wash-in. Fig. 14 shows that after 20-30 
s’ permeabilization, Ca2+ sparks were detected in myocytes after 20 min 
exposure to F-FKBP12.6, F-CaM and fluo-4. In this case there is no visible 
striated pattern abservable for F-FKBP12.6 or F-CaM or FRET. This indicates 
that fluo-4 can enter the cell but that CaM and FKBP12.6 can not. For the 3 min 
permeabilization, both FRET striation pattern and Ca2+ sparks were detected 
indicating that all 3 probes entered the cell. This experiment indicates that 20-30 
s’ permeabilization can effectively prevent FKBP12.6 and CaM wash-off during 
the time of Ca2+ spark measurement. Thus, we can make Ca2+ spark 
measurement in the relatively native cellular environment with respect to CaM 
and FKBP12.6 presence.
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Fig 14: Effect of different time permeabilization. A, 30 sec 
permeabilization only fluo4 can enter the cell. B, 3 min 
permeabilization can make F-FKBP12.6, F-CaM and fluo4 enter the 
cell.
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Using this approach, we evaluated diastolic SR Ca2+ leak by recording 
Ca2+ sparks within 15-20 min after permeabilization. Fig 15A-B shows that, at 
baseline ([Ca2+] = 50nM), Ca2+ spark frequency was significantly increased in 
RyR2+/ADA mice versus WT (8.85 ± 0.26 vs 6.4 ± 0.51 /s per 100 μm), while SR 
Ca2+ content appeared slightly but insignificantly decreased for RyR2+/ADA
mutants (Fig 15B). The increase of Ca2+ spark frequency could not be inhibited 
by AIP, the specific CaMKII inhibitor (Fig 15B). This is consistent with the 
reduced CaM binding to RyR2 allowing higher RyR2 activity, and rule out the 
potential contribution of CaMKII activity to this observation. Ca2+ spark properties 
(Ca2+ spark amplitude, full duration at half-maximum, full width at half-maximum, 
and maximum Ca2+ release) were unchanged (Fig. 16). Then we increased 
intracellular [Ca2+] slightly to 100nM, close to the threshold for Ca2+ wave 
production, to further test the propensity for DADs or arrhythmogenesis. The 
increased [Ca2+] mimics a Ca2+ loading stress in permeabilized cells, since both 
cytosolic and SR Ca2+ load are increased. We can see that for RyR2+/ADA mutant 
mice ~90% of myocytes produced Ca2+ waves, but for WT mice only ~10% of 
myocytes produce Ca2+ waves (Fig 15C, D) while no significant difference in Ca2+
SR load was detected (Fig 15D). All these data indicate that the ADA mutation in 
RyR2, which caused CaM dissociation from RyR2, increases diastolic SR Ca2+
leak under resting conditions and leads to a significantly higher propensity for 
arrhythmogenic Ca2+ wave production under moderate Ca2+ loading condition. 
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Fig 15: Diastolic Ca2+ leakiness in RyR2ADA/+ mice. A, at 50nM 
[Ca2+], representative confocal line-scan Ca2+ spark images for WT and 
RyRADA/+ mice. B, quantification of Ca2+ spark frequency and SR Ca2+
content for WT and RyR2ADA/+ mice (+AIP). C, at 100nM [Ca2+],
representative confocal line-scan Ca2+ wave images for RyR2ADA/+ mice, but 
not for WT. D, % of cells (n=8) that produced Ca2+ waves and the SR Ca2+
content for WT and RyR2ADA/+ mice. 
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Fig 16: Ca2+ spark characteristics for permeabilized myocytes. A,
Ca2+ spark full duration at half-maximum (FDHM). B. Ca2+ spark maximum 
release. C. Ca2+ spark amplitude. D. Ca2+ spark full width at half-maximum 
(FWHM).
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Ca2+ transients for RyR2+/ADA KI mouse in intact myocytes 
We also measured Ca2+ transients in intact ventricular myocytes (Fig 17A) 
with or without isoproternol (ISO, 50 nM) present, and SR Ca2+ content was 
evaluated through rapid caffeine application. In 1 Hz field stimulation for the 
basal level, the myocytes from RyR2+/ADA mutant behave as WT in Ca2+ transient 
amplitude, time constant of Ca2+ transient decline, SR Ca2+ content and fractional 
SR Ca2+ release (Fig 17B-E). However, exposure to 50nM ISO revealed 
differences including prolonged time constant of Ca2+ transient decline, 
decreased SR Ca2+ content and increased fractional SR Ca2+ release (Fig 17C-
E). At the same time, for the RyR2+/ADA mutant, there is a major increase of 
propensity for Ca2+ wave and triggered activity under ISO conditions (Fig 18).  
Indeed, the induction of Ca2+ waves that can trigger action potential in the 
presence of ISO indicates significant arrhythmogenic risk when CaM binding to 
RyR2 is inhibited. With Ca2+ loading via 50nM ISO, in RyR2+/ADA KI myocytes, the 
highly sensitized RyR2 can contribute to  the prolonged Ca2+ transient decline, 
SR Ca2+ depletion and higher fractional release, but resulting in relatively normal 
Ca2+ transient amplitude ( similar as WT). 
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Fig 17: Ca2+ transients in intact myocytes. A, representative Ca2+
transient (?[Ca2+]i) under 1 Hz stimulation and SR Ca2+ load with/without 
isoproternol (50nM) for WT and RyR2ADA/+ mice. B, average twitch transient 
amplitude (F/F0). C, time constant of twitch [Ca2+]i decline. D, SR Ca2+
content. E, fractional Ca2+ release expressed as the ratio for twitch Ca2+
transient over caffeine Ca2+ release in absence or presence 50nM 
isoproternal.
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Fig 18: Ca2+ wave and triggered activities for RyR2ADA/+ mice. A,
representative line-scan image of Ca2+ wave and triggered activity in intact 
cardiomyocytes with 50 nM isoproterenol. B, the percentage of cells that 
exhibited Ca2+ waves and triggered activities for WT (n=24) and RyR2ADA/+ 
(n=22) mouse myocytes under 50nM isoproternol.
0
20
40
60
%
 o
f C
el
ls
wave
W
T A
D
A
/+
W
T
A
D
A
/+
1 s
10
 µ
m
1 Hz Stimulation Ca
2+ Wave
Triggered Activities
Triggered 
Activities
A
B
%
 o
f C
el
ls
W
T A
D
A
/+
W
T
A
D
A
/+
10
 µ
m
95
Binding affinity (Kd) of CaM/FKBP12.6 to RyR2 in HF myocytes. 
To further examine the CaM binding affinity under a pathological condition, 
we measured the CaM-RyR2 binding affinity in a rat HF model induced by 
coronary ligation. In this rat HF model, HF developed in 12 weeks post-surgery. 
In this HF model an increased heart/body weight ratio, increased LV diastolic 
dimensions (LVDD) and decreased fractional shortening were observed (Lin et 
al, 2007). Other HF molecular markers, like ANP, BNP, and TNF-? were also 
found significantly increased in this HF model (Lin et al, 2007). Here we only 
used HF rats with LVDD > 1.1 cm (normal: 0.9) and fractional shortening < 20% 
(normal: 43%) for experiments. Through FRET detection and steady-state 
concentration-dependent binding, the Kd for CaM-RyR2 measured in HF 
myocytes is 50.9 ± 4.4 nM (Fig 19A). Compared to the Kd for normal myocytes, 
there is a ~3 fold decrease in CaM affinity for the rat HF model. To exclude the 
possible strain/species difference, we performed additional control experiments. 
We tested the CaM-RyR binding in control vs HF rats in the Kd range of [CaM] 
and at saturating [CaM] (Bmax) (Fig 19C). In the Kd range, which is sensitive to 
detect affinity changes, we see a significant decrease in CaM binding to RyR2 for 
HF myocytes, indicating a decreased binding affinity, but unchanged Bmax for 
CaM binding. FKBP12.6 has been suggested to also be a critical RyR2 stabilizer 
whose affinity changes in HF, despite the intensive controversy (Bers, 2012). 
We, for the first time, examined the FKBP12.6-RyR2 binding in situ affinity in HF 
myocytes. Through steady-state binding measurement, the Kd for FKBP12.6-
96
RyR2 is 0.84 ± 0.07 nM (Fig 19B). This is almost unchanged in comparison to 
our previous control Kd value (Kd = 0.7 ± 0.07nM measured in the same 
conditions (Guo et al, 2010)). To more careful test for differences, the same 
paired control experiments as done for CaM were performed. Fig 19D shows that 
FKBP12.6 binding was unaltered when [FKBP12.6] was in either the Kd range or 
saturating condition in control vs HF rat myocytes. 
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Fig 19: Kd for CaM/FKBP12.6 binding to RyR2 in HF myocytes. A, 
Using FRET detection (as in Figure 1) and steady-state binding isotherms, we 
measured an increase in the Kd (decrease in affinity) of CaM-RyR2 binding in 
HF myocytes, but we detected no significant change in the FRETmax. B, 
Using direct excitation of  FKBP12.6, and steady-state binding isotherms, we 
detected no significant differences in the FKBP12.6-RyR2 binding in HF and 
normal myocytes. C, At sub-saturating [A-CaM] (?Kd), there is a significant 
decrease in CaM bound to RyR2 in HF myocytes, but there is no significant 
change in FRETmax (at saturating A-CaM). D, for Kd range or saturated 
condition (Bmax), the FKBP12.6-RyR2 associate rate are unchanged for 
normal and HF myocytes 
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DISCUSSION 
In this study through fluorescent protein and FRET detection, we for the 
first time identify CaM bound to RyR2 vs its other targets and characterize CaM-
RyR2 interaction properties (Kd and on/off rates) in permeabilized ventricular 
myocytes by 3 independent methods (Table 1). The knock-in mice, with 
genetically disrupted CaM-RyR2 association but no effects on other CaM binding 
targets, are used to estimate the percentage of Z-line CaM that is bound to 
RyR2. And the patho-physiologically functional consequences of CaM for RyR2 
regulation are defined through confocal Ca2+ measures at myocytes in RyR2ADA/+
KI mice. We further define the in situ CaM-RyR binding affinity in HF myocytes to 
reveal a potential pathological role of reduced CaM binding in RyR2 regulation. 
All these results could lead to a crucial improvement for understanding and 
definition of CaM-RyR2 interaction in cardiac myocytes in health and disease. 
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Table 1. Summary of CaM-RyR2 binding properties 
kon (x106min-1M-1) koff (min-1) Kd (nM)
Wash-in/off
FRAP
Steady-state
18.9 ± 1.6
14.5 ± 2.5
--
0.22 ± 0.01
0.144 ± 0.05
--
12 ± 0.9
10 ± 2
18.2 ± 2
100
CaM-RyR2 binding properties in the myocytes  
CaM, as an important RyR2 regulator, may be important in HF, cardiac 
hypertrophy and CPVT. But CaM-RyR2 in situ binding properties are unknown. 
Through 3 independent methods, we showed that CaM can bind to RyR2 with 
high affinity (Kd = 10-20 nM) in resting condition, where [Ca2+]i is 50nM. In this 
condition, according to the measured free [CaM] in myocytes (50-75 nM) (Wu X, 
et al, 2007), ~70-90% of RyR2 monomers are associated with CaM, which 
makes CaM a potential important RyR2 stabilizer, because CaM is associated 
with the majority of RyR2 monomers and inhibits RyR2 opening at all 
physiological [Ca2+]. Our measured binding affinity is higher than the result from 
cell lysates and SR vesicles (Guo et al, 2011; Ono et al, 2010). We think that 
could be due to differences of experiment conditions. In lysates and SR vesicles 
experiments, there is a higher risk of losing essential partners from the cellular 
environment or causing subtle modification to RyR2 (such as: phosphorylation or 
oxidation). And phosphorylation, oxidation, or conformation change can 
dramatically decrease CaM-RyR2 binding affinity (Xu et al, 2010; Balog et al, 
2006). Our results for CaM-RyR2 binding affinity, from 3 independent methods, 
matched each other quite well, and fit with CaM’s physiological function. So we 
believe the Kd (10-20 nM) better reflects the binding affinity for CaM-RyR2 in the 
native cardiac myocyte environment.
According to our data, CaM-RyR2 has a relatively slow off rate (koff = ~ 0.2 
min-1), meaning the average dwell time for CaM on RyR2 is ~5 min in resting 
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condition. In addition, high [Ca2+]i (500 nM) favors CaM binding to Z-line and 
greatly prolongs CaM dissociation time and increases the affinity (Guo et al, 
2011; Wu et al, 2007). So the increased CaM-RyR2 affinity during the Ca2+
transient (< 1 second) during which intracellular [Ca2+] could be as high as 
handreds micromolar; this would further enhance CaM saturation at all RyR2 
monomers in the physiological beat-to-beat situation. Furthermore, it was 
proposed that CaM can switch between two binding sites with 33Å distance on 
RyR during each cycle of contraction (Tripathy et al, 1995; Samso and 
Wagenknecht 2002). The two-site switch involves two sets of association and 
dissociation process, which might be unlikely to occur within the very short 
systolic Ca2+ time according to our measured kinetics. Taken together, we think 
that CaM is a residently associated protein to RyR2 and is anchored to at least 
residues 3583-3603. But we can not exclude the possibility of beat-to-beat RyR2 
regulation by CaM, because in RyR2ADA/ADA mutant sustained peak time for Ca2+ 
transient were observed, indicating the possible importance of resident CaM for 
RyR2 shut-off (Yamaguchi et al, 2007). It is possible that, during Ca2+ transient, 
RyR opening and conformation change could alter anchored CaM function, 
where binding of Ca2+ to CaM would facilitate the termination of Ca2+ release. 
Nearly all Z-line bound CaM is on RyR2 
One of the important aspects in this study is that, through knock-in mice 
(RyR2ADA/+) we estimate that > 90% of total Z-line associated CaM is on RyR2, 
meaning ~1.1 μM CaM is associated with RyR2. This result is consistent with 
102
FKBP12.6 Bmax measurements (Guo et al, 2010) and the estimated concentration 
of RyR2 monomers in rat ventricular myocytes (Bers and Stiffel, 1993), revealing 
that other CaM binding sites at the Z-line are ~0.07μM. Since LTCC is also 
known to bind CaM and at the same location as RyR2, and there are ~32 RyR2 
monomers per LTCC in rat myocytes (Bers and Stiffel, 1993), the calculated 
LTCC-bound CaM could be ~0.04 uM consistent with our result. We can see that 
RyR2 is the quantitatively dominant CaM binding site at the Z-line. The total 
cellular CaM concentration in cardiac myocytes is about 2-5 μM in different 
species (Maier et al, 2006). From this we can see that RyR2 is also an overall 
major binding site for CaM, and that any binding affinity variation in RyR2, like in 
HF, could cause changes in cellular free [CaM] and consequent distribution.  
Defective RyR2-CaM interaction and SR Ca2+ release 
Yamaguchi (2007) explained the important link between CaM-RyR2 
interaction and abnormal SR Ca2+ leak, and cardiac hypertrophy in RyR2ADA
homozygous mice. But, due to the early death of RyR2ADA homozygous mice 
(Yamaguchi et al, 2007), the relation between defective CaM-RyR2 interaction 
and arrythmogenesis is not clear. However, RyR2ADA heterozygous mice can 
survive to provide us an excellent model for our study. We notice a similarity 
between RyR2ADA KI mice and CPVT1 mutation KI mice (RyR2-R2474S) 
(Stephan et al, 2008), that is both homozygous KI mice do not survive but 
heterozygous can survive similar to WT. Furthermore, decreased CaM-RyR2 
binding affinity has been reported in CPVT1 KI mice (Xu et al, 2010). So for 
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functional tests, we focused on the SR Ca2+ release under stress conditions in 
RyR2ADA heterozygous mice. In permeabilized cells, when [Ca2+]i is tightly 
controlled at 50 nM, we only observed a moderate Ca2+ spark frequency increase 
for RyR2ADA/+ mice. This moderate Ca2+ leakiness explains why the heterozygous 
mice could survive as long as WT, unlike homozygous RyR2ADA mice which 
developed severe cardiac hypertrophy and early death. For the CPVT1 mutant, 
spontaneous Ca2+ releases (Ca2+ waves) which can trigger DADs, are a typical 
phenomena. In our case the diastolic Ca2+ leak at resting condition in RyR2ADA/+
is insufficient to produce Ca2+ waves and triggered arrhythmias unless SR Ca2+
load is driven up by external stimulus (i.e., stress or exercise). Then we 
increased intracellular [Ca2+] to 100 nM to load the SR and this produced Ca2+
waves significantly in RyR2ADA/+ mice, which indicates the hypersensitized RyR2. 
There are two reasons which could be behind this phenomenon. 1), the 
increased SR Ca2+ content over the threshold releases more Ca2+ than in resting 
condition during the SR Ca2+ leak; 2), possible endogenous CaMKII activation, 
due to increased free [CaM] (released by 50% defective CaM-RyR2 interaction) 
and high Ca2+, which could activate endogenous CaMKII then further 
phosphorylate and sensitize RyR2 to amplify the leakiness.
For the Ca2+ transient measurements in intact cells, ISO makes a big 
difference in RyR2ADA/+ mice. We observe a prolonged Ca2+ transient decline time 
constant. Since Yamaguchi (2007) reported that there is no change for Ca2+
uptake by the SR CaATPase for RyR2ADA/+ mice (Yamaguchi et al, 2007), we 
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think that the prolonged Ca2+ decline might be due to delayed RyR2 closure, 
which is consistent with single channel recording where CaM-RyR2 interaction 
facilitates termination of Ca2+ release (Xu et al, 2004). Under ISO stimulation, 
there is a decreased SR Ca2+ content and an increased fractional SR Ca2+
release for RyR2ADA/+ mice, indicating the sensitized RyR2 by CaM dissociation 
could increase systolic SR Ca2+ release. Additionally, with the presence of ISO, 
there is an increase of the propensity for Ca2+ waves and triggered activity (Fig 
18).  This phenomenon is very similar to the situation in CPVT1 KI mice 
(Uchinoumi H, et al, 2010). In resting condition, there is a mild diastolic Ca2+ leak 
(Fig 17B) with unchanged Ca2+ transients and fractional release. But under ISO 
stimulation, we see a dramatically increased propensity for Ca2+ wave and trigger 
activity. The ADA mutation on RyR2 is not a known human disease linked 
mutation, but it causes very similar phenotype as CPVT mutations. These results 
imply a strong link between defective RyR2-CaM interaction and 
arrhythmogenesis, and the potential mechanism underlying arrhythmia. 
CaM-RyR2 binding affinity in HF myocytes 
One of the most important aims for this study is to define the in situ 
binding affinity for RyR2-CaM in HF myocytes and access potential pathological 
impact of that. Our result indicates a 3-fold decreased binding affinity for RyR2-
CaM interaction in failing heart induced by MI.  HF causes a reduced RyR2-CaM 
association, from 70-90% to 50-70%, assuming unchanged free myocyte [CaM]. 
Using IP other studies have also reported less CaM bound to RyR2 in HF in 
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rabbits (Ai et al, 2005) and dogs (Ono M, et al, 2010), so this seems like a 
general finding in HF. Less CaM association can decrease RyR2 gating 
threshold, causing abnormal Ca2+ release and triggered activation. In RyRADA/+ 
mice, we revealed that 50% reduction of RyR2 association leads to dramatically 
increased propensity for Ca2+ wave and trigger activity in the presence  of 
isoproterenol.  In our HF model, the RyR2-CaM association rate is close to 50% 
level, revealing a strong link between CaM-RyR2 disassociation to 
arrhythmogenesis in HF. Furthermore, the attenuated RyR2-CaM association in 
HF could increase intracellular free [CaM], since RyR2 is a major cellular binding 
site for CaM. This could change CaM cellular distribution extensively; the CaM 
lost by RyR2 could be driven to the binding targets with a lower affinity than 
RyR2, such as: CaMKII and adenylyl cyclase (Maier and Bers, 2002). Further 
study is needed to assess such CaM redistribution and its effect in HF.  
Overall we think that HF associated SR Ca2+ leak is a complicated process 
in which many factors may be involved (e.g. CaM, CaMKII, FKBP12.6, redox 
modification etc). Even though in normal myocytes saturating RyR2 with 
FKBP12.6 only slightly reduces Ca2+ sparks (Guo et al, 2010), we could not 
exclude the possibility that FKBP12.6 might inhibit pathological leaky RyRs. 
Here, we for the first time have directly measured the in situ binding affinity of 
RyR2-FKBP12.6 in failing heart myocytes, which revealed unchanged binding 
affinity. We conclude that CaM binding to RyR2 is an important physiological 
106
regulator of RyR2 gating in cardiac myocytes, and that defects in this binding in 
HF or CPVT may be an important molecular mechanism of triggered arrhythmias. 
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CHAPTER VI 
Define CaM as a critical stabilizer through RyR2 unzipping 
peptide (DPc10) 
INTRODUCTION
A leading hypothesis explains the RyR2 dysfunction in HF and lethal arrhythmias, 
such as catecholaminergic polymorphic ventricular tachycardia (CPVT), by RyR2 
mutations that result in defective interaction between the N-terminal (N: 0-600) 
and the central (C: 2000-2500) domains (Yamamoto T & Ikemoto 2002). 
According to this concept, in the resting state, the N-terminal and central 
domains interact with each other to act as a regulatory switch for channel gating 
activity. This tight interdomain interaction, termed “domain zipping” serves to 
stabilize the closed channel. Weakening of these interdomain interactions may 
be caused by mutations in either the N-terminal or central regions of RyR2
(Uchinoumi et al, 2010) or via synthetic competition by cardiac domain peptides 
(Ikemoto & Yamamoto 2002; Ikemoto 2004; Yamamoto et al, 2000) (domain 
unzipping), resulting in an increased opening probability of the RyR2 and 
leakiness of Ca2+. DPc10 is a synthetic peptide corresponding to 36-residue 
stretch of the central domain (Gly2460-Pro2495) of RyR2 (Yamamoto & Ikemoto 
2002). It has been proposed that DPc10 can specifically associate with the N-
terminal domain, and thus compete with its zipping to the central domain, and 
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that the N-domain/DPc10 association can destabilize RyR2 (via domain 
unzipping), to increase Ca2+ leakiness (Oda et al, 2005). A single R2474S point 
mutation in DPc10 (DPc10-mut) inhibits all of the effects that would have been 
produced by DPc10. Liu et al (2005), through GFP insertion and mapping, 
showed a physical proximity between N- and central domains in the 3D structure 
of RyR2.  They also find FRET interaction between these two regulatory domains 
for CFP/YFP insertion in HEK cell, but the zipping pair (N- and central domains) 
is not from the same RyR2 monomer, but from two different neighbor subunits in 
one RyR2, indicating the interaction of neighboring subunits plays important role 
to stabilize RyR2 (Liu et al, 2010). Taken together, these data suggest that 
synthetic domain peptides bind to key subdomains of RyR2 and are capable of 
mimicking disease conditions of the RyR2 channel by interfering with interdomain 
interactions. The interaction between neighbor subunits is important for the RyR2 
stabilization. 
FKBP12 and FKBP12.6 are expressed in cardiac myocytes and can form 
tight complexes with RyR2, at a stoichiometry of four FKBPs per tetrameric RyR2 
channel (Bers, 2004). As such, these FKBP isoforms are considered important 
RyR2 subunits, and have been reported to promote the closed channel state, but 
this role is controversial in the heart. In myocytes from normal rat hearts, we 
found that FKBP12 does not significantly alter Ca2+ sparks, whereas FKBP12.6 is 
slightly inhibitory, and PKA-dependent RyR2 phosphorylation does not alter 
FKBP12.6 binding affinity (Guo et al, 2010). Furthermore, a small fraction of 
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RyR2 in native myocytes has FKBP12.6 bound (Guo et al, 2010). Two previous 
studies, in which RyR2 was treated with domain peptides to mimic pathologic 
Ca2+ leakage, found no direct effect of DPc10 on FKBP12.6 co-immu-
noprecipitation with RyR2 (Oda et al, 2005; Tateishi et al, 2009). But it is 
unknown whether FKBP12.6 influences binding of DPc10 to RyR2 or the ensuing 
increased Ca2+ leakage.
CaM is a ubiquitous Ca2+ binding protein that binds to the RyR2 and 
modulates its channel function (Yamaguchi et al, 2003). Binding of CaM within 
the cytosolic domain of RyR2 (at a site partly formed by residues 3583-3603) 
inhibits channel activity both at physiological and pathophysiological cellular 
[Ca2+] (Fruen et al, 2000; Balshaw et al, 2002). This implies that CaM stabilizes 
the closed state of RyR2 in the resting state (Guo et al, 2006).  In the 3D RyR2 
structure, the CaM binding site is very close to the boundary between adjacent 
subunits (Hamilton & Serysheva II, 2009).  There is the suggestion that CaM 
binds to two adjacent subunits of RyR (Zhang et al, 2002), and contributes to 
stabilization. Interestingly, concurrent-addition of a high concentration of CaM 
with DPc10 in WT cardiomyocytes reduced the Ca spark frequency compared to 
addition of DPc10 alone (Ono et al, 2010). Furthermore, in the CPVT mutant 
myocytes where beta-adrenergic stimulation leads to defective interdomain 
interaction, the affinity of CaM binding to the RyR2 is lower than that of WT 
myocytes (Xu et al, 2010). In addition, Ono et al (2010) also reported that the 
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CaM binding affinity to RyR2 in the failing heart is significantly reduced compared 
to that of normal RyR2. 
DPc10 and related RyR2 peptides may, therefore, serve as useful 
molecular probes to study the channel’s function-structure relationship. However, 
the details of DPc10 binding to RyR2, including affinity and kinetics, are still 
unknown. In this study, our goal was to characterize the binding of DPc10 to the 
RyR2 in the relatively intact environment of saponin-permeabilized rat ventricular 
myocytes. We used fluorescent DPc10 to measure the affinity and kinetics of 
DPc10 binding to RyR2, and its influence on CaM and FKBP12.6 binding and 
function, and how DPc10 alters CaM and FKBP12.6 binding.   
MATERIALS AND METHODS 
Domain peptide 
DPc10 peptides unlabeled and labeled with 5-carboxyfluorescein or HiLyte 
FluorTM 647 at N-terminal were synthesized at AnaSpec (Fremont, CA).  The 
DPc10 sequence is:
2460-GFCPDHKAAMVLFLDRVYGIEVQDFLLHLLEVGFLP-2495. 
Laser scanning confocal microscopy 
Confocal images were measured using a Biorad Radiance 2100 laser 
scanning confocal microscope equipped with an Argon ion laser, Green HeNe 
laser and a Nikon Fluo 40 x oil objective lens. FRET between CaM and DPc10 
were performed on Olympus FV1000 confocal microscope. All experiments were 
done at room temperature 
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F-DPc 10 washin/off in permeabilized myocytes 
See details in chapter IV 
Ca2+ sparks in permeabilized cells using confocal microscopy 
See details in chapter IV 
FRET measurements 
For the FRET between CaM and DPc10, we used Alexa Fluor 568 
attached at the C-lobe of CaM (AF568-110-CaM) or Alexa Fluor 488 at N-lobe 
(AF488-34-CaM) as the donor, and HiLyte FluorTM647-DPc10 (HF647-DPc10) as 
the acceptor. AF488, AF568- and HF647- were excited with separate lasers of 
488 nm, 543 nm and 635 nm, respectively. Emission fluorescence intensity data 
were obtained at 500-530 nm for AF488-34-CaM, 560-620 nm for AF568-110-
CaM and 655-755 nm for HF647-DPc10.  Fig 20 shows the spectrum of FRET 
probes.
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Fig 20: Fluorescence spectrum for FRET (adopted from 
invitrogen.com)
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RESULTS
Binding kinetics of F-DPc10 in permeabilized cardiac myocytes 
To characterize DPc10 binding kinetics at the Z-lines, we performed F-
DPc10 wash-in (500 nmol/L), wash-off experiments in permeabilized myocytes 
(Fig 21A). We observed very slow association (?wash-in = 79.0 ± 3.2 min) and 
dissociation processes (?wash-out = 149.8 ± 4.4 min), compared to FKBP12.6 
measurements (Guo T, et al, 2010). From the wash-in/wash-off measurements, 
we calculated the association and dissociation rates constants, kon and koff,
according to:
   kwash-in = [F-DPc10]kon + koff   Eq 1 
where kwash-out ? koff and k = 1/? (s). Accordingly, kon = 188 ± 37 (s-1 M-1),
and koff = 0.12 ± 0.01 (10-3 s-1).  Based on these values and Kd = koff/kon, F-DPc10 
binds at the Z-line with Kd = 644 ± 149 nmol/L. 
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Fig 21: F-DPc10 binding at the myocyte Z-line (collaboration with 
Oda Tetsuro). A, striation pattern of saponin-permeabilized myocytes 
incubated in 5 μmol/L F-DPc10 for 3 hours, and illustration of DPc10 
binding pocket between N-(blue) and central (red) domains in RyR2. B,
Time course of F-DPc10 (0.5 μmol/L) wash-in and wash-out.
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We were intrigued by the slow kin, and conducted measurements to further 
understand the structural basis of this slow association. Thus, we tested the 
hypothesis that, at resting [Ca2+]i, normally RyR2 is in closed situation, where N- 
and central domains are in the tightly zipped condition, which sterically hindered 
DPc10 access to its RyR2 binding site. If the N-terminal and central domains are 
tightly “zipped” to each other, this interaction may occlude the DPc10 binding site 
on the RyR2, thus limiting the DPc10 kon. Alternatively, a limiting factor may be 
the rate at which DPc10 adopts a conformation that is competent to bind to 
RyR2. To discern between these mechanisms, we determined the effect of [F-
DPc10] on kin which should increase linearly with [F-DPc10], according to Eq 1. 
This is not what was observed, however.  Instead, a 10-fold increase in [F-
DPc10] (from 0.5 to 5μmol/L) had no significant effect on the ?wash-in of F-DPc10 
but significantly increased Bmax (Fig 21A, B). This result suggests that F-DPc10
association at its RyR2 binding site is restricted by a factor residing on RyR2, 
which is probably the binding pocket opening rate. 
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Fig 22: Wash-in time course for different [F-DPc10] (collaboration
with Oda Tetsuro). A, Time course wash-in curve for different [F-DPc10] 
(0.5 and 5μmol/L).  B ?wash-in and Bmax for different [F-DPc10]. Data are 
reported as mean ± SE.  
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In our working model, under resting conditions, the RyR closed state is 
stabilized by the interaction between the N-terminal and central domain in the 
"zipped" state. We hypothesized that conditions that promote RyR opening will 
result in a higher rate of unzipping, and a faster F-DPc10 wash-in rate. To test 
this, we first monitored F-DPc10 wash-in at elevated Ca2+ (500 nmol/L) and 
found slightly faster association vs. 50nmol/L [Ca2+]i (Fig 23A).  Next, we pre-
incubated the myocytes with ryanodine (100 μmol/L) plus caffeine (5 mmol/L), 
which has been reported to cause RyR2 domain unzipping in HEK293 cells (Liu 
Z, et al, 2010), and found a significantly faster F-DPc10 association (Fig 23B). 
However, the most significant effect was seen after pre-incubating myocytes with 
a saturating concentration of non-fluorescent DPc10 (NF-DPc10). This treatment 
significantly accelerated F-DPc10 association by a factor of ~2 (Fig 23A). Neither 
treatment significantly altered Bmax (Fig 23A & B).  Assuming that koff of NF-
DPc10 is the same as for F-DPc10 and using Eq 1, the kon is increased by 3.2-
fold by unzipping by prebinding NF-DPc10 to the RyR2. These results are 
consistent with a small fraction of channels being in the unzipped state even at 
500 nmol/L Ca2+ or wih caffeine +ryanodine.  Moreover, it would seem that the 
RyR2 open state (favored by caffeine-ryanodine) differs from the unzipped state 
(with DPc10 bound).
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Fig 23: Effect of RyR2 channel modulators on the kinetics of F-
DPc10 Z-line association (collaboration with Oda Tetsuro). A, Time 
course of F-DPc10 (0.5 μmol/L) Z-line binding in low [Ca2+]i, high [Ca2+]i, or 
after a 3 hr pre-equilibration with saturating [NF-DPc10] (2 μmol/L) in low 
[Ca2+]i . B, Time course of F-DPc10 (5 μmol/L) Z-line binding after a 3 hr 
pre-equilibration in internal solution containing ryanodine (100 μmol/L) and 
caffeine (5 mmol/L). Data are reported as mean ± SE.
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Effect of DPc10 on CaM and FKBP12.6 binding at the myocyte Z-line 
Both FKBP12.6 and CaM bind to the RyR2 and can reduce channel 
opening, which might inhibit DPc10 binding.  Fig 24A shows representative 
confocal images of FKBP12.6 (100 nmol/L) and CaM (1 μmol/L) effects on F-
DPc10 binding, as detected after a 200 min incubation with F-DPc10. While pre-
equilibration with CaM (1 μmol/L) greatly reduced F-DPc10 binding, pre-
treatment with FKBP12.6 (100 nmol/L) did not alter F-DPc10 binding in 
permeabilized myocytes. Fig 24B shows the time course of F-DPc10 wash-in 
with or without pretreatment of 100 nmol/L FKBP12.6 or 1 μmol/L CaM.  
Saturation of RyR2 with FKBP12.6 (100 nmol/L) did not alter either F-DPc10 
maximal binding (Bmax) or ?wash-in. In contrast, saturation of RyR2 with CaM 
dramatically reduced F-DPc10 Bmax and dramatically slowed DPc10 access to its 
binding site, as indicated by the increase in ?wash-in (Fig 24C). We infer that CaM 
stabilizes the domain interaction between N-terminal and central domains in the 
"zipped" state, and may thereby reduce DPc10 access to its binding site.
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Fig 24: Effects of FKBP12.6 and CaM on F-DPc10 binding at Z-
line.  A, Representative confocal images illustrating the effect of FKBP12.6 
(100 nmol/L), and CaM (1 μmol/L) on the F-DPc10 (5 μmol/L) binding at 
the Z-lines. B, Time course of F-DPc10 (5 μmol/L) wash-in (circles), and in 
the presence of FKBP12.6 (100 nmol/L, diamonds) or CaM (1 μmol/L, 
triangles). C, Summary of fitting parameters (Bmax and ?wash-in).
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Next, we asked whether RyR channel activation by DPc10 is inhibited by 
FKBP12.6 or CaM. We assessed Ca2+ sparks in permeabilized myocytes 
perfused with internal solution containing 50 nmol/L free Ca2+ plus 1 μmol/L AIP 
(to inhibit CaMKII activity). Line-scan images were recorded after 3 hr 
incubations under control conditions, and in the presence of 5 μmol/L DPc10, 
with or without 1 μmol/L CaM or 100 nmol/L FKBP12.6 (Fig 25A). DPc10 robustly 
increased Ca2+ spark frequency (CaSpF) vs. control, an effect almost completely 
blocked by CaM (Figure 25B). However, CaSpF activation by DPc10 is only 
slightly decreased by FKBP12.6 (Fig 25B). In DPc10-treated permeabilized 
myocytes, Ca2+ spark full width at half maximum (FWHM) and full duration at half 
maximum (FDHM) is significantly increased compared to control, and decreased 
when pre-treated with CaM ( Table 2). 
Since Ca2+ spark frequency strongly depends on the SR Ca2+ content, we 
also assessed SR Ca2+ content as the amplitude of caffeine-induced Ca2+
transient (Fig 25B, right). With DPc10 alone or with FKBP12.6, SR Ca2+ load was 
significantly lower than under control conditions. In contrast, treatment with CaM 
plus DPc10 resulted in no significant decrease in SR Ca2+ content vs control. 
Thus, the increased CaSpF in the presence of FKBP12.6 plus DPc10 cannot be 
secondary to increased SR Ca2+ content, which actually decreased. These 
results are consistent with a DPc10-induced increase in RyR2 channel activity 
resulting from defective interaction between N-terminal and central domains. This 
also agrees with the lack of FKBP12.6 effect on F-DPc10 binding kinetics (Fig 
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25B) and the potent inhibition of DPc10 binding by CaM, which may promote the 
“zipped” state and inhibit DPc10 access.
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Fig 25: Effects of FKBP12.6 and CaM on DPc10 binding and Ca2+
sparks in permeabilized cardiomyocytes (collaboration with Oda 
Tetsuro). A, Ca sparks measured using Fluo-4 as Ca2+ indicator. 
Representative line-scan images acquired after addition of DPc10 (5 
μmol/L), DPc10 (5 μmol/L) plus FKBP12.6 (100 nmol/L), and DPc10 (5 
μmol/L) plus CaM (1 μmol/L). [Ca2+]i = 50 nmol/L.  B, Summary of Ca2+
spark frequency and SR Ca2+ content. Data are reported as mean ± SE. 
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No. of 
Sparks
Peak 
(F/F0)
FWHM
(µm)
FDHM 
(ms)
Control 1761 0.499 ± 0.004 1.28 ± 0.01 55.7 ± 0.67
+DPc10 1467 0.475 ± 0.004* 1.34 ± 0.01* 58.5 ± 1.00*
+FKBP12.6/DPc10 1921 0.439 ± 0.002* 1.21 ± 0.01* 60.5 ± 0.73*
+CaM/DPc10 2195 0.467 ± 0.003* 1.23 ± 0.01* 56.9 ± 0.74
Table 2. Ca2+ spark characteristics in saponin-permeabilized 
cardiomyocytes 
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Effect of DPc10 on FKBP12.6 and CaM binding in permeabilized myocytes  
To examine the converse influence that DPc10 may have on FKBP12.6 
and CaM binding to RyR2 in situ, we used fluorescent FKBP12.6 and CaM 
variants labeled with Alexa Fluor 488 or 568 (AF488 and AF568, respectively).
These fluorescent proteins were added to saponin permeabilized myocytes with 
or without pre-equilibration with saturating DPc10 concentration. First, we found 
that AF488-FKBP12.6 at a 1 nmol/L (near its Kd) (Guo T, et al, 2010), forms a 
striated pattern that is not affected by pre-incubation of 5 μmol/L DPc10. (Fig 26A 
& B). Thus, DPc10 does not influence FKBP12.6 binding to RyR2.  Next, we 
measured FRET between AF488-FKBP12.6 (donor) and AF568-34-CaM 
(acceptor in the N-domain) at a [CaM] near the Kd (20 nmol/L), in order to only 
detect CaM that is specifically bound to the RyR2 (Fig 27A).  Using direct 
excitation at 543 nm (emission at >600 nm) we detected total CaM at the Z-lines 
(Fig 27A). We also did this with high [CaM] (500 nmol/L) which saturates RyR2 
with CaM under control conditions. Fig 27B shows that pre-treatment with DPc10 
significantly reduced CaM binding (at 20 nmol/L CaM) both at the RyR2 and 
overall at the Z-lines, and by similar proportions. Even at high AF568-34-CaM 
levels (500 nmol/L) DPc10-treated myocytes exhibited reduced CaM binding at 
the RyR2 (FRET) and at the Z-lines (Total) vs. control (Fig 27B). Thus, once F-
DPc10 binds to the RyR2 and decreases N-terminal-central domain interactions, 
it reduces the CaM affinity for RyR2. Taken together, these results show that 
DPc10 and CaM binding to RyR2 are mutually inhibitory.  To test whether DPc10 
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and CaM bind at the same or nearby RyR2 sites we measured FRET between 
CaM and DPc10.
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Fig 26: The effect of DPc10 on FKBP12.6 binding to RyR2 in 
cardiac myocytes (collaboration with Oda Tetsuro). A. Representative
image for FKBP12.6 binding (100nM) with or without DPc10 (5μM) 
pretreatment. B. Average fluorescence for FKBP12.6 binding with/without 
DPc 10.
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Fig 27: The effect of DPc10 on CaM binding to RyR2 in cardiac 
myocytes (collaboration with Oda Tetsuro). A. Representative confocal 
image of the effect of DPc10 on AF568-CaM binding at the Z-lines (total 
CaM, Ex =543 nm) and at the RyR2 detected by FRET between AF488-
FKBP12.6 (donor) and AF568-CaM (acceptor) (Ex =488 nm). Myocytes were 
incubated with 5 μmol/L DPc10 (3 hrs) before adding CaM. B. Summary of 
RyR2-bound CaM and Z-line total CaM binding of DPc10 pretreatment.
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FRET between CaM and DPc10 
We used FRET to assess the distance between a fluorescence donor 
probe (AF568) at the C-lobe of CaM (AF568-110-CaM) and HiLyte Fluor 647 
(HF647) as acceptor probe on the N-terminus of DPc10 (HF647-DPc10).  We 
utilized the acceptor photobleaching approach with measurement of the resultant 
increase in donor (AF568-110-CaM) fluorescence in saponin permeabilized 
myocytes.  To use this approach quantitatively, all acceptor sites must be loaded, 
so that all donors can participate in FRET.
Our results show that it is impractical to saturate RyR2 with both CaM and 
DPc10 (Fig 24B and 27B). To overcome this challenge, we pre-equilibrated the 
myocytes with saturating HF647-DPc10, thus loading all DPc10 binding sites on 
RyR2. Then when we add AF568-110-CaM (500 nmol/L) ~50% of RyR2s have 
donor, but all have acceptor, allowing quantitative analysis of enhanced donor 
fluorescence upon acceptor photobleach.  Fig 28A shows selective photobleach 
of HF647-DPc10 (at 635 nm) in only the central region of the myocyte, and donor 
fluorescence was enhanced only in that region, indicating that donors and 
acceptors are within FRET range.
To rule out the possibility that there is energy transfer between a donor 
and multiple acceptors, we measured the relationship between donor 
fluorescence enhancement and acceptor photobleach, and found a linear 
relationship (Fig 28B), which indicates that there is a 1:1 stoichiometry for the 
CaM-DPc10 FRET.  We interpret this result as clear evidence that the FRET 
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efficiency (E) between AF568-110-CaM and HF647-DPc10 reflects the proximity 
of one CaM to one DPc10. E and donor-acceptor distance calculations are 
described in the  methods section (chapter IV). 
The FRET efficiency between AF568-110-CaM and HF647-DPc10 upon 
98.2 ± 0.2 % acceptor photobleach was E= 0.89 ± 0.01 (n=8). This corresponds 
to a distance of 53 ± 1 Å (Fig 28C), based on R0 = 75 Å for the AF568-HF647 
donor-acceptor pair. With an alternative donor probe (AF488), this time attached 
at the N-lobe of CaM, and the same acceptor (HF647) on DPc10, we measured 
E= 0.27 ± 0.02 which corresponds to an interprobe distance of 63 ± 1 Å (Fig 
28C). Thus, this result shows that the donor probes on CaM are 53-63 Å from the 
acceptor on DPc10, suggesting that CaM and DPc10 can simultaneously bind at 
distinct, yet nearby sites within the RyR2 structure. This again favors an allosteric 
rather than competitive basis for the mutual inhibition seen between CaM and 
DPc10 binding to the RyR2.
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Fig 28: FRET between F-CaM and F-DPc10. A, Confocal images 
show FRET between AF568-110-CaM (donor) and HF647-DPc10 
(acceptor). B, AF568-110-CaM fluorescence intensity increase on HF647-
DPc10 photobleach. Data is fitted by a linear function, indicating that the 
ratio between donor and acceptor is 1:1. C, FRET efficiency and 
distances between AF568-110-CaM and HF647-DPc10, and between 
AF488-34-CaM and HF647-DPc10.  
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DISCUSSION 
We used fluorescent DPc10, FKBP12.6, CaM and confocal microscopy of 
permeabilized cardiomyocytes and found that (1) DPc10 access to its binding 
site is sterically hindered in resting (zipped) RyR2, (2) F-DPc10 wash-in kinetics 
provide a sensitive measure of the RyR2 unzipped state in permeabilized 
myocytes, (3) DPc10 and CaM binding to RyR2 are mutually inhibitory (via 
allosteric rather than competitive interaction), and (4) DPc10 and CaM are 
physically 50-60 Å from each other.
Access of DPc10 to Its RyR2 Binding Site Is Restricted 
We found that both the wash-in and wash-off kinetics of F-DPc10 binding 
(kwash-in and kwash-off) are extremely slow (Fig 21B). The calculated kon for F-DPc10 
is about 1800-fold slower than that we measured for FKBP12.6 under similar 
conditions (Guo T, et al, 2010).  This suggests either that DPc10 very slowly 
adopts a conformation that can bind RyR2, or that the DPc10 binding site on 
RyR2 becomes available only very slowly. The insensitivity of kwash-in to higher F-
DPc10 concentration (Fig 22A), is most consistent with the latter interpretation, 
indicating that kon is limited by RyR2 properties that restrict the access of DPc10 
to its binding site. Further supporting this hypothesis, pretreatment with NF-
DPc10 (Fig 23A) robustly increased kon (~320%).  We infer that the bound NF-
DPc10 shifted RyR2 to the unzipped state allowing better access and exchange 
with F-DPc10. We also found that enhancing RyR2 open state (by elevated 
[Ca2+] or caffeine+ryanodine) hastened the F-DPc10 association (Fig 23A, B).  
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However, these effects on kwash-in were small compared to that of pre-binding NF-
DPc10 (~15%), despite the very strong channel activation expected.  From this 
and other work (Liu et al, 2010), we suggest that the unzipped and open states 
differ, although unzipping may enhance opening and opening may enhance the 
unzipping transition (and DPc10 access). 
Relationship between FKBP12.6 and DPc10 binding to RyR2 
FKBP12.6 has been found to quiet RyR2 channel opening (Prestle et al. 
2001; Xin et al. 2002; George et al. 2003; Yano et al. 2003), but this is an 
intensely controversial issue (Timerman et al. 1996; Barg et al. 1997; Xiao et al. 
2007; Jones et al. 2008; Bers 2012) and FKBP12.6 may only inhibit 
pathologically leaky RyRs (Yano M, et al, 2000). Since more than 80% of the 
RyRs in cardiomyocytes have no natively-bound FKBP12.6 (Guo T, et al, 2010), 
adding saturating concentrations of exogenous FKBP12.6 ought to decrease 
Ca2+ leak caused by DPc10-induced unzipping. Here, we found that FKBP12.6 
has no effect on either DPc10 binding (Bmax or ?wash-in) or vice-versa (Fig 24B and 
Fig 26) and does not quiet the activating effect of DPc10 on the CaSpF (Fig 
25B). That is similar to our previous myocyte studies, where FKBP12.6 had very 
minor effects on Ca2+ sparks (Guo et al, 2010).  Taken together, these results 
suggest that DPc10 and FKBP12.6 modulate RyR2 function through independent 
mechanisms.   
Relationship between CaM and DPc10 Binding to RyR2 
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In myocytes containing a CPVT-linked RyR2 mutation ?-adrenergic
stimulation decreases CaM binding at the Z-lines, and this effect is mimicked in 
healthy myocytes by treatment with DPc10 (Ono et al, 2010).  Here, we used 
methods designed to monitor CaM and DPc10 binding specifically at RyR2, 
aiming to understand the structural basis of the inhibition of CaM-RyR binding by 
DPc10. One important finding in the present study is that saturating CaM binding 
at the RyR2 dramatically reduced F-DPc10 binding and Ca2+ spark activation (Fig 
24 & 25), presumably by stabilizing the zipped RyR2 state.
Our novel FRET-based method allows direct assessment of CaM-RyR 
binding in the native cardiac myocyte environment (using FKBP12.6-CaM FRET) 
(Guo et al, 2011). Using this method, we found that unzipping the RyR by 
treatment with saturating [DPc10], reciprocally inhibits CaM binding to RyR2 (Fig 
26B, right panel).  There are two possible explanations for this reciprocal binding 
inhibition: (1) DPc10 and CaM compete to bind at overlapping sites (orthosteric 
mechanism) or (2) the DPc10 and CaM binding sites are separate but coupled in 
a mutually inhibitory interaction (allosteric mechanism).
To discern between these possibilities we assessed if CaM and DPc10 
can coexist on RyR2. In Fig 27A, we show strong FRET between donor-labeled 
CaM and acceptor-labeled DPc10 at the Z-lines, indicating that CaM and DPc10 
binding sites in neighboring regions are simultaneously occupied. This 
conclusion is further supported by FRET measurements using two different 
donor-acceptor pairs and two different labeling sites on CaM, which indicate 
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distances of 63 ± 1 and 53 ± 1 Å between DPc10 and the N- and C-lobes of 
CaM, respectively (Fig 28C). Taken together, these results strongly support the 
conclusion that DPc10 and CaM bind at separate sites on RyR2, and they 
interact through an allosteric mutually inhibitory mechanism.
Our working hypothesis (Fig 29) is as follows.  The resting zipped RyR2 
does not readily allow DPc10 access to its site (i) and CaM binding at a different 
site may stabilize this zipped state (iii). We suppose the RyR2 can transition 
spontaneously between this zipped and the unzipped state (i-ii) but that the low 
probability at rest cause the slow, but eventual access of DPc10 to its site. This 
transition may be favored by channel opening (Ca2+, caffeine, ryanodine) and 
also in pathological conditions (e.g. HF).  Once the central domain-mimicking 
DPc10 gains access and binds, it stabilizes the unzipped state (ii) which 
reciprocally facilitates channel opening and inhibits CaM binding (iv).  
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Fig 29: Proposed model of the interaction between N-terminal 
and central domains.  Kinetics results (Figures 2-4) suggest that F-DPc10 
access to its binding site is controlled by inter-domain interaction within 
RyR2. (i) The F-DPc10 access is sterically hindered in resting normal 
RyR2 (“zipped” state). (ii) Pre-treatment of RyR2 with physiological, 
pharmacological, or disease-mimetic agents that promote unzipping 
increase the F-DPc10 association rate. (iii) CaM inhibits the F-DPc10 
binding to RyR2. (iv) DPc10 binding to RyR2 inhibits CaM binding to RyR2. 
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CHAPTER VII 
SUMMARY 
The aim of my dissertation is to understand the regulation of RyR2. The 
whole dissertation is composed of two parts. The first part focused on RyR2-CaM 
interaction. The second focused on synthetic RyR2 domain peptide (DPc10), 
which worked as a powerful molecular tool for RyR2 functional and structural 
studies.
CaM has been long identified as an important cardiac RyR regulator. 
Broad studies suggest CaM is a critical RyR2 stabilizer (Xu L, et al, 2004, Guo T, 
et al, 2006) and CaM-RyR2 interaction is a critical molecular substrate for 
arrhythmias and HF pathogenesis (Yamaguchi N, et al, 2007; Ai X, et al, 2005; 
Ono M, et al, 2010; Xu X, et al, 2010), but the in situ binding properties for CaM-
RyR2 are still unknown. Here we, Using FRET detection and permeabilized 
myocytes, identified RyR2-bound CaM from other potential targets and revealed 
that CaM binds to RyR2 with high affinity (Kd =10-20 nM) in myocytes. Therefore 
physiologically CaM is bound to > 70% of RyR2 monomers and inhibits SR Ca2+
release.  Using RyR2ADA/+ knock-in mice in which half of the RyR2-CaM binding 
is suppressed, we estimated that >90% of Z-line CaM is RyR2-bound and identify 
RyR2 as one of main CaM cellular binding sites.  In consistence with binding 
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properties studies, functional tests indicated a higher propensity for Ca2+ waves 
in RyR2ADA/+ mice upon ISO challenge. In a post MI rat HF model, I detected a 
decrease binding affinity for CaM-RyR2 (Kd = ~51nM, ~3 fold increase) and 
unchanged binding affinity for FKBP12.6-RyR2 (Kd = ~0.8nM). 
The defective interaction between interdomains (the N-terminal and the 
central domains) is a leading hypothesis to explain the RyR2 dysfunction in HF 
and lethal arrhythmias, such as CPVT. And DPc10 can bind to RyR2 and 
recapitulate this arrhythmogenic RyR2 leakiness by unzipping N- and central-
domains. In this study fluorescently-labeled DPc10, FKBP12.6, and CaM were 
used to characterize the binding properties of DPc10 to RyR2 in permeabilized 
rat ventricular myocytes. DPc10 access to its binding site is extremely slow in 
resting RyR2, but accelerated by promoting RyR2 opening or unzipping (by 
unlabeled DPc10). RyR2-bound CaM (but not FKBP12.6) drastically slowed 
DPc10 binding. Conversely, DPc10 binding significantly reduced CaM (but not 
FKBP12.6) binding to the RyR2. FRET measurements indicate that DPc10 and 
CaM binding sites are separate.
Since CaM and FKBP12.6 are both regarded as important RyR stabilizer 
and implicated broadly in HF, hypertrophy and arrhythmia genesis. And 
FKBP12.6 is still a highly controversial issue in cardiology (this was reviewed in 
chapter II, FK-506 Binding Protein section). Here, mainly based on the data from 
our lab, I made a brief comparison between these two important RyR2 
stabilizers, which suggested CaM has more prominent effect for RyR2 gating 
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than FKBP12.6 does.  However, I can’t exclude the possibility that FKBP12.6 
may modulate RyR2 activities in a subtle way which is undetectable by our 
experiment, like non-spark Ca2+ leak by RyR2.
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Table 3. Comparison between CaM and FKBP12.6 as RyR2 stabilizer 
(a), Wu x, et al, 2006 
(b), Guo T, et al, 2010 
(c), Yamaguchi N, et al, 2007 
(d), Wehrens X, et al, 2003 
(e), Guo T, et al, 2006 
 CaM FKBP12.6 
Kd and RyR2 
monomer
association rate 
High affinity (Kd = 10-20nM), 
intracellular [CaM] = 50-70nM 
(a), 70-90% RyR2 monomers 
are associated with CaM. 
High affinity (Kd = 1nM), 
but low endogenous 
FKBP12.6, 10-20% RyR2 
monomers are associated 
with FKBP12.6. (b)
Phenotype of 
bioengineered
mice
RyR2ADA knock-in mice, in 
homozygous, severe 
hypertrophy and early death. 
(c)
FKBP12.6 knock-out mice, 
no obvious phenotype at 
resting condition. (d)
Kd in HF 
myocytes
Increased No change 
Ca2+ spark 
inhibition in 
myocytes in  
staturated
condition
50-70% decrease (e) ~20% decrease (b)
Association can 
keep RyR2 in 
zipping
condition
Yes No 
If RyR2 is in 
unzipping state  
Kd (RyR2-CaM) increased  No change for Kd (RyR2-
FKBP12.6)
142
Future studies
For the future studies, these projects can be taken further to address the 
specific reasons for pathologically decreased CaM-RyR2 affinity, like: (1) 
phosphorylation by PKA or CaMKII, because the phosphorylation sites (S2808 by 
PKA and S2814 by CaMKII) are close to CaM docking pocket in RyR2 3D 
structure (Xing M, et al, 2007), (2) RyR2 modification by redox. For DPc10 
studies, F-DPc10 wash-in kinetics can be used in the more native environment of 
permeabilized cardiomyocytes to evaluate domain interaction between the N-
terminal and central domains of RyR2. This could serve as a powerful and 
versatile investigative tool in pre-clinical and clinical studies with respect to the 
domain unzipping hypothesis.  For example, the time course of F-DPc10 wash-in 
can be monitored in myocytes from failing hearts in which “unzipped” state had 
already taken place (Oda T, et al, 2005; Ono M, et al, 2010), or to gauge RyR2 
function under pathological conditions (e.g., oxidative stress, phosphorylation 
state etc) and in the evaluation (or validation) of drug candidates that act to 
stabilize the RyR2 “zipped” state (Oda T, et al, 2005).
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